

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ABALOPARATIDE

**Products Affected**

- TYMLOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ABATACEPT IV

**Products Affected**

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: 1): TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# ABATACEPT SQ

**Products Affected**

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# ABEMACICLIB

**Products Affected**

- VERZENIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ABIRATERONE

**Products Affected**

- *abiraterone acetate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ABIRATERONE SUBMICRONIZED

**Products Affected**

- YONSA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ACALABRUTINIB

**Products Affected**

- CALQUENCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MANTLE CELL LYMPHOMA: INTOLERANCE TO BRUKINSA. CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA: INTOLERANCE TO BRUKINSA OR IMBRUVICA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ADAGRASIB

---

**Products Affected**

- KRAZATI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ADALIMUMAB

### Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
<b>Other Criteria</b>	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): 1) TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. HS: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR HS OR TNF INHIBITORS FOR ANY INDICATION. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, PSA, AS, PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER</p>

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AFATINIB

**Products Affected**

- GILOTRIF

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ALECTINIB

---

**Products Affected**

- ALECENSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ALPELISIB-PIQRAY

**Products Affected**

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AMIKACIN LIPOSOMAL INH

**Products Affected**

- ARIKAYCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AMIVANTAMAB-VMJW

**Products Affected**

- RYBREVANT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ANAKINRA

### Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
<b>Required Medical Information</b>	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. CAPS, DIRA: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION.

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## APALUTAMIDE

### Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## APOMORPHINE - SL

**Products Affected**

- KYNMOBI
- KYNMOBI TITRATION KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## APREMILAST

**Products Affected**

- OTEZLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING 2 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., PUVA [PHOTOTHERAPY], UVB [ULTRAVIOLET LIGHT B], TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). RENEWAL: MILD PSO, BEHCETS DISEASE: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA, MODERATE TO SEVERE PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ARIMOCLOMOL

**Products Affected**

- MIPLYFFA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ASCIMINIB

**Products Affected**

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ASFOTASE ALFA

**Products Affected**

- STRENSIQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ATOGEPANT

**Products Affected**

- QULIPTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AVACOPAN

**Products Affected**

- TAVNEOS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AVAPRITINIB

**Products Affected**

- AYVAKIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AXITINIB

---

**Products Affected**

- INLYTA ORAL TABLET 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AZACITIDINE

---

**Products Affected**

- ONUREG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## AZTREONAM INHALED

**Products Affected**

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	7 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BEDAQUILINE

**Products Affected**

- SIRTURO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 WEEKS
<b>Other Criteria</b>	PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB): SIRTURO USED IN COMBINATION WITH AT LEAST 3 OTHER ANTIBIOTICS FOR THE TREATMENT OF PULMONARY MDR-TB.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BELIMUMAB

### Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BELUMOSUDIL

**Products Affected**

- REZUROCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BELZUTIFAN

**Products Affected**

- WELIREG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BENDAMUSTINE

**Products Affected**

- BENDAMUSTINE HCL  
INTRA VENOUS SOLUTION
- *bendamustine hcl intravenous solution reconstituted*
- BENDEKA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BENRALIZUMAB

**Products Affected**

- FASENRA
- FASENRA PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-2 INHIBITOR) FOR EGPA. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EGPA: 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EGPA</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BETAINE

**Products Affected**

- *betaine*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BEVACIZUMAB-ADCD

**Products Affected**

- VEGZELMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BEVACIZUMAB-AWWB

**Products Affected**

- MVASI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BEVACIZUMAB-BVZR

**Products Affected**

- ZIRABEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BEXAROTENE

**Products Affected**

- *bexarotene*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## **BINIMETINIB**

**Products Affected**

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BORTEZOMIB

**Products Affected**

- *bortezomib injection*
- BORUZU

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BOSENTAN

### Products Affected

- bosentan*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BOSUTINIB

**Products Affected**

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## BRIGATINIB

**Products Affected**

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## C1 ESTERASE INHIBITOR-HAEGARDA

**Products Affected**

- HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTING: C1INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CABOZANTINIB CAPSULE

**Products Affected**

- COMETRIQ (100 MG DAILY DOSE)  
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)  
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CABOZANTINIB TABLET

### Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CANNABIDIOL

**Products Affected**

- EPIDIOLEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# CAPIVASERTIB

**Products Affected**

- TRUQAP ORAL TABLET
- TRUQAP TABLET THERAPY PACK  
160 MG ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CAPMATINIB

**Products Affected**

- TABRECTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CARGLUMIC ACID

### Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
<b>Other Criteria</b>	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CERITINIB

**Products Affected**

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CERTOLIZUMAB PEGOL

### Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: 1) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR 2) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. PSA: 1) ONE OF THE FOLLOWING: (A) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR (B) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX,

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ENBREL, HUMIRA, STELARA, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR (B) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA, STELARA, SKYRIZI, TREMFYA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) ONE OF THE FOLLOWING: (A) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR (B) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA, XELJANZ, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. CD: 1) ONE OF THE FOLLOWING: (A) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR (B) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: STELARA, HUMIRA, RINVOQ, SKYRIZI, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. PJIA: 1) ONE OF THE FOLLOWING: (A) PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT, OR (B) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ IR, ORENCIA, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. RENEWAL: CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. RA: CONTINUES TO BENEFIT FROM MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND</p>

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CETUXIMAB

**Products Affected**

- ERBITUX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CLADRIBINE

### Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 48 WEEKS.
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): INITIAL: HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH). RENEWAL: 1) HAS DEMONSTRATED CLINICAL BENEFIT COMPARED TO PRE-TREATMENT BASELINE, 2) DOES NOT HAVE LYMPHOPENIA, AND 3) HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CLOBAZAM-SYMPAZAN

**Products Affected**

- SYMPAZAN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	LGS: 1) UNABLE TO TAKE TABLETS OR SUSPENSIONS, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF CLOBAZAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## COBIMETINIB

**Products Affected**

- COTELLIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CORTICOTROPIN

**Products Affected**

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS AUTO-INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	Yes

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## CRIZOTINIB CAPSULE

### Products Affected

- XALKORI ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# CRIZOTINIB PELLETS

**Products Affected**

- XALKORI ORAL CAPSULE SPRINKLE  
 150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DABRAFENIB CAPSULES

**Products Affected**

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## DABRAFENIB SUSPENSION

**Products Affected**

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNABLE TO SWALLOW TAFINLAR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DACOMITINIB

**Products Affected**

- VIZIMPRO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DALFAMPRIDINE

### Products Affected

- *dalfampridine er*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA. RENEWAL: IMPROVEMENT IN WALKING ABILITY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DAROLUTAMIDE

### Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MHSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DASATINIB

### Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DATOPOTAMAB DERUXTECAN-DLNK

**Products Affected**

- DATROWAY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**DECITABINE/CEDAZURIDINE**

**Products Affected**

- INQOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DEFERASIROX

### Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF DRY LIVER WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF DRY LIVER WEIGHT OR GREATER.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL (CHRONIC IRON OVERLOAD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL (CHRONIC IRON OVERLOAD): DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.
<b>Indications</b>	All FDA-approved Indications.

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DENOSUMAB-XGEVA

**Products Affected**

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DEUTETRABENAZINE

**Products Affected**

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DICLOFENAC TOPICAL SOLUTION

**Products Affected**

- *diclofenac sodium external solution 2 %*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1% TOPICAL GEL AND A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DIMETHYL FUMARATE

**Products Affected**

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DIROXIMEL FUMARATE

**Products Affected**

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DOSTARLIMAB-GXLY

**Products Affected**

- JEMPERLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DRONABINOL CAPSULE

**Products Affected**

- *dronabinol*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D FOR THE INDICATION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DROXIDOPA

### Products Affected

- *droxidopa*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DUPILUMAB

### Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. ATOPIC DERMATITIS (AD): AD COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR AD AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: AD, PRURIGO NODULARIS (PN): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL: AD, CRSWNP, EOE, PN: 6 MOS, ASTHMA, COPD: 12 MOS. RENEWAL: ALL INDICATIONS: 12 MOS.
<b>Other Criteria</b>	INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR), AND 3) NO CONCURRENT USE

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>WITH OTHER SYSTEMIC BIOLOGICS OR JAK INHIBITORS FOR AD. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PN: 1) CHRONIC PRURITIS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID OR CALCIPOTRIOL). EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EOSINOPHILIC COPD. RENEWAL: AD: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK INHIBITORS FOR AD. EOE: IMPROVEMENT WHILE ON THERAPY. CRSWNP: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS</p>

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITIS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EOSINOPHILIC COPD, AND 3) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## DUVELISIB

**Products Affected**

- COPIKTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## EFLORNITHINE

**Products Affected**

- IWILFIN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ELACESTRANT

**Products Affected**

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ELAGOLIX

### Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ELRANATAMAB-BCMM

### Products Affected

- ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ELTROMBOPAG - ALVAIZ

### Products Affected

- ALVAIZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN 30 X 10 <sup>9</sup> /L FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT IS LESS THAN 50 X 10 <sup>9</sup> /L FROM AT LEAST 2 SEPARATE LABS IN THE LAST 3 MONTHS AND HAD A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ELTROMBOPAG - PROMACTA

**Products Affected**

- PROMACTA ORAL PACKET 12.5 MG, 25 MG
- PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN 30 X 10 <sup>9</sup> /L FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS, OR 2) PLATELET COUNT OF LESS THAN 50 X 10 <sup>9</sup> /L FROM AT LEAST 2 SEPARATE LAB TESTS IN THE LAST 3 MONTHS AND A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS) OR SPLEEN TYROSINE KINASE (SYK) INHIBITOR. ALL INDICATIONS: APPROVAL FOR PROMACTA ORAL SUSPENSION PACKETS REQUIRES A TRIAL OF PROMACTA TABLET OR PATIENT IS UNABLE TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS OR SYK INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ENASIDENIB

---

**Products Affected**

- IDHIFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ENCORAFENIB

### Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ENTRECTINIB CAPSULES

### Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ENTRECTINIB PELLETS

**Products Affected**

- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ENZALUTAMIDE

**Products Affected**

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: ALL INDICATIONS: 12 MONTHS. RENEWAL: MCRPC, NMCRPC, MCSPC: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E. RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CRPC (MCRPC), NMCRPC, METASTATIC CSPC (MCSPC), NMCSPC : 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: MCRPC, NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## EPCORITAMAB-BYSP

### Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## EPOETIN ALFA-EPBX

**Products Affected**

- RETACRIT INJECTION SOLUTION                      UNIT/ML, 4000 UNIT/ML, 40000  
10000 UNIT/ML, 10000 UNIT/ML(1ML),            UNIT/ML  
2000 UNIT/ML, 20000 UNIT/ML, 3000

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS LESS THAN 13G/DL. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
<b>Other Criteria</b>	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ERDAFITINIB

**Products Affected**

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ERLOTINIB

### Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ESKETAMINE

**Products Affected**

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST.
<b>Coverage Duration</b>	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ETANERCEPT

### Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, PSA, AS, PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## EVEROLIMUS-AFINITOR

**Products Affected**

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## EVEROLIMUS-AFINITOR DISPERZ

### Products Affected

- *everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FECAL MICROBIOTA CAPSULE

**Products Affected**

- VOWST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 DAYS
<b>Other Criteria</b>	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FEDRATINIB

**Products Affected**

- INREBIC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FENFLURAMINE

### Products Affected

- FINTEPLA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	DRAVET SYNDROME: INITIAL/RENEWAL: 12 MONTHS. LGS: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. RENEWAL: DRAVET SYNDROME: PATIENT HAS SHOWN CONTINUED CLINICAL BENEFIT (E.G. REDUCTION OF SEIZURES, REDUCED LENGTH OF SEIZURES, SEIZURE CONTROL MAINTAINED).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# FENTANYL CITRATE

**Products Affected**

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FEZOLINETANT

**Products Affected**

- VEOZAH

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) EXPERIENCES 7 OR MORE HOT FLASHES PER DAY, AND 2) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS). RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (I.E., PERSISTENT HOT FLASHES), AND 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**FILGRASTIM-AAFI**

**Products Affected**

- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FINERENONE

---

**Products Affected**

- KERENDIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# FINGOLIMOD

**Products Affected**

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FOSCARBIDOPA-FOSLEVODOPA

### Products Affected

- VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PD: INITIAL: 1) RESPONSIVE TO LEVODOPA, 2) CURRENT REGIMEN INCLUDES AT LEAST 400 MG/DAY OF LEVODOPA, AND 3) MOTOR SYMPTOMS ARE CURRENTLY UNCONTROLLED (DEFINED AS AN AVERAGE OFF TIME OF AT LEAST 2.5 HOURS/DAY OVER 3 CONSECUTIVE DAYS WITH A MINIMUM OF 2 HOURS EACH DAY). RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FREMANEZUMAB-VFRM

### Products Affected

- AJOVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FRUQUINTINIB

**Products Affected**

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## FUTIBATINIB

**Products Affected**

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GALCANEZUMAB-GNLM

**Products Affected**

- EMGALITY
- EMGALITY (300 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
<b>Other Criteria</b>	INITIAL: MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: MIGRAINE PREVENTION: 1) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY, AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. EPISODIC CLUSTER HEADACHE: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# GANAXOLONE

**Products Affected**

- ZTALMY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GEFITINIB

**Products Affected**

- *gefitinib*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GILTERITINIB

**Products Affected**

- XOSPATA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GLASDEGIB

**Products Affected**

- DAURISMO ORAL TABLET 100 MG,  
25 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GLATIRAMER

**Products Affected**

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GLP1-DULAGLUTIDE

### Products Affected

- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GLP1-SEMAGLUTIDE

**Products Affected**

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
- OZEMPIC (2 MG/DOSE)
- RYBELSUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GLP1-TIRZEPATIDE

### Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GOSERELIN

### Products Affected

- ZOLADEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
<b>Other Criteria</b>	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## GUSELKUMAB

**Products Affected**

- TREMFYA INTRAVENOUS
- TREMFYA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>AUTOIMMUNE INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: PSO, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## HIGH CONCENTRATION ORAL OPIOID SOLUTIONS

**Products Affected**

- *morphine sulfate (concentrate) oral solution 100 mg/5ml*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	OPIOID TOLERANT: 12 MONTHS. HOSPICE, PALLIATIVE CARE OR END OF LIFE CARE: LIFETIME.
<b>Other Criteria</b>	1) OPIOID TOLERANT (I.E. PREVIOUS USE OF 60 MG ORAL MORPHINE PER DAY, 25 MCG TRANSDERMAL FENTANYL PER HOUR, 30 MG ORAL OXYCODONE PER DAY, 8 MG ORAL HYDROMORPHONE PER DAY, 25 MG ORAL OXYMORPHONE PER DAY, 60 MG ORAL HYDROCODONE PER DAY, OR AN EQUIANALGESIC DOSE OF ANOTHER OPIOID) AND HAS TROUBLE SWALLOWING OPIOID TABLETS, CAPSULES, OR LARGE VOLUMES OF LIQUID, OR 2) ENROLLED IN HOSPICE OR PALLIATIVE CARE OR END OF LIFE CARE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IBRUTINIB

**Products Affected**

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ICATIBANT

### Products Affected

- *icatibant acetate subcutaneous solution  
prefilled syringe*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	HAE: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR TREATMENT OF ACUTE HAE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IDELALISIB

**Products Affected**

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IMATINIB

### Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IMATINIB SOLUTION

**Products Affected**

- IMKELDI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
<b>Other Criteria</b>	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IMETELSTAT

**Products Affected**

- RYTELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INAVOLISIB

**Products Affected**

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INFIGRATINIB

**Products Affected**

- TRUSELTIQ (100MG DAILY DOSE)
- TRUSELTIQ (125MG DAILY DOSE)
- TRUSELTIQ (50MG DAILY DOSE)
- TRUSELTIQ (75MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CHOLANGIOCARCINOMA: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INFLIXIMAB

### Products Affected

- infliximab*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. PSA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA, STELARA, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSO: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA, STELARA, SKYRIZI, TREMFYA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA, XELJANZ, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. MODERATE TO SEVERE CD: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA, HUMIRA, RINVOQ, SKYRIZI, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA, XELJANZ, HUMIRA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. AS, PSO, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC, MODERATE TO SEVERE CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INSULIN SUPPLIES PAYMENT DETERMINATION

---

### Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- ALCOHOL SWABSTICK PAD
- ALCOHOL SWABSTICK PAD 70 %
- APLICARE ALCOHOL SWABSTICK PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 0.5 ML (OTC)
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- BD AUTOSHIELD 29G X 5MM
- BD AUTOSHIELD 29G X 8MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 25G X 1" 1 ML
- BD INSULIN SYRINGE 25G X 5/8" 1 ML
- BD INSULIN SYRINGE 26G X 1/2" 1 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 0.5 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE U-500 31G X 6MM 0.5 ML
- BD INSULIN SYRINGE U/F 30G X 1/2" 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 1 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD PEN NEEDLE MICRO U/F 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO U/F 32G X 4 MM (OTC)
- BD PEN NEEDLE NANO U/F 32G X 4 MM (RX)
- BD PEN NEEDLE ORIGINAL U/F 29G X 12.7MM
- BD PEN NEEDLE SHORT U/F 31G X 8 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD SWABS SINGLE USE BUTTERFLY PAD
- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML (OTC)
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML (RX)
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML (OTC)
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML (RX)
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML (OTC)
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML (RX)
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH ALCOHOL PREP PAD 70 %
- CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH PEN NEEDLES 29G X 12MM
- CARETOUCH PEN NEEDLES 31G X 5 MM
- CARETOUCH PEN NEEDLES 31G X 6 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- CARETOUCH PEN NEEDLES 31G X 8 MM
- CARETOUCH PEN NEEDLES 32G X 4 MM
- CARETOUCH PEN NEEDLES 32G X 5 MM
- CARETOUCH PEN NEEDLES 33G X 4 MM
- CLEVER CHOICE COMFORT EZ 29G X 12MM
- CLEVER CHOICE COMFORT EZ 33G X 4 MM
- CLICKFINE PEN NEEDLES 31G X 6 MM
- CLICKFINE PEN NEEDLES 31G X 8 MM
- CLICKFINE PEN NEEDLES 32G X 4 MM
- COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PEN NEEDLES 33G X 4 MM
- COMFORT EZ PEN NEEDLES 33G X 5 MM
- COMFORT EZ PEN NEEDLES 33G X 6 MM
- COMFORT EZ PEN NEEDLES 33G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM
- EASY COMFORT PEN NEEDLES 32G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 5 MM
- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- EASY TOUCH FLIPLOCK INSULIN SYR 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS 1ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- FREESTYLE PRECISION INS SYR 30G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 30G X 5/16" 1 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 1 ML
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 0.3 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGE 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 29G X 1/2" 0.3 ML
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GOODSENSE ALCOHOL SWABS PAD 70 %
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (OTC)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)
- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN ULTRAFIN 29G X 12MM
- INSUPEN ULTRAFIN 31G X 8 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"
- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 8 MM
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLES 29G X 12MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 31G X 5 MM (OTC)
- PEN NEEDLES 31G X 8 MM (OTC)
- PEN NEEDLES 32G X 4 MM (OTC)
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 1 ML
- PRECISION SURE-DOSE SYRINGE 29G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 3/8" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 31G X 8 MM
- PRO COMFORT PEN NEEDLES 32G X 4 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELI-ON INSULIN SYRINGE 29G 0.5 ML
- RELI-ON INSULIN SYRINGE 29G X 1/2" 1 ML
- RELION ALCOHOL SWABS PAD
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE-PREP ALCOHOL PREP PAD 70 %
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TERUMO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUEPLUS PEN NEEDLES 29G X 12MM
- TRUEPLUS PEN NEEDLES 31G X 5 MM
- TRUEPLUS PEN NEEDLES 31G X 6 MM
- TRUEPLUS PEN NEEDLES 31G X 8 MM
- TRUEPLUS PEN NEEDLES 32G X 4 MM
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTICARE MICRO PEN NEEDLES 32G X 4 MM
- ULTICARE MINI PEN NEEDLES 30G X 5 MM
- ULTICARE MINI PEN NEEDLES 31G X 6 MM
- ULTICARE MINI PEN NEEDLES 32G X 6 MM
- ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)
- ULTICARE PEN NEEDLES 29G X 12.7MM (RX)
- ULTICARE PEN NEEDLES 31G X 5 MM
- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTILET INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE 31G X 1/4" 0.3 ML
- ULTILET INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (OTC)
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.3 ML (RX)
- ULTILET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- ULTILET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 1/2" 0.3 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE SHORT 30G X 5/16" 1 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.3 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 0.5 ML
- ULTILET INSULIN SYRINGE SHORT 31G X 5/16" 1 ML
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME
<b>Other Criteria</b>	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**INTERFERON FOR MS-AVONEX**

**Products Affected**

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INTERFERON FOR MS-BETASERON

### Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INTERFERON FOR MS-PLEGRIDY

**Products Affected**

- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## INTERFERON GAMMA-1B

### Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IPILIMUMAB

### Products Affected

- YERVOY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
<b>Other Criteria</b>	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IVACAFTOR

### Products Affected

- KALYDECO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
<b>Other Criteria</b>	CF: INITIAL: NOT HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE. RENEWAL: 1) MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR 2) REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IVOSIDENIB

**Products Affected**

- TIBSOVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## IXAZOMIB

---

**Products Affected**

- NINLARO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LANREOTIDE

**Products Affected**

- LANREOTIDE ACETATE
- SOMATULINE DEPOT  
SUBCUTANEOUS SOLUTION 60  
MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	ACROMEGALY: INITIAL: 3 MOS, RENEWAL: 12 MOS.GEP-NETS, CARCINOID SYNDROME: 12 MOS.
<b>Other Criteria</b>	ACROMEGALY: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE GENERIC OCTREOTIDE INJECTION. RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LAPATINIB

### Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# LAROTRECTINIB

**Products Affected**

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LAZERTINIB

**Products Affected**

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LEDIPASVIR-SOFOSBUVIR

**Products Affected**

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. REQUESTS FOR HARVONI 45MG-200MG PELLETS: PATIENT IS UNABLE TO SWALLOW TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LENALIDOMIDE

**Products Affected**

- *lenalidomide*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LENVATINIB

**Products Affected**

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LETERMOVIR

### Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
<b>Other Criteria</b>	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# LEUPROLIDE

**Products Affected**

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LEUPROLIDE DEPOT

**Products Affected**

- LEUPROLIDE ACETATE (3 MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LEUPROLIDE-ELIGARD

**Products Affected**

- ELIGARD

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LEUPROLIDE-LUPRON DEPOT

**Products Affected**

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
<b>Coverage Duration</b>	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
<b>Other Criteria</b>	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LEUPROLIDE-LUPRON DEPOT-PED

**Products Affected**

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVELS OF FOLLICLE-STIMULATING HORMONE (FSH) GREATER THAN 4.0 MIU/ML AND LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVELS OF FSH GREATER THAN 5.0 MIU/ML AND LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## L-GLUTAMINE

### Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# LIDOCAINE OINTMENT

**Products Affected**

- *lidocaine external ointment 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LIDOCAINE PATCH

**Products Affected**

- *lidocaine external patch 5 %*
- *lidocan*
- ZTLIDO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	1) PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA, 2) NEUROPATHY DUE TO DIABETES MELLITUS, 3) CHRONIC BACK PAIN, OR 4) OSTEOARTHRITIS OF THE KNEE OR HIP.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**LIDOCAINE PRILOCAINE**

**Products Affected**

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LONCASTUXIMAB TESIRINE-LPYL

**Products Affected**

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# LORLATINIB

**Products Affected**

- LORBRENA ORAL TABLET 100 MG,  
 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LOTILANER

**Products Affected**

- XDEMVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 WEEKS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## LUMACAFITOR-IVACAFITOR

### Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTIC FIBROSIS (CF): CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CF.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: RENEWAL: 1) MAINTAINED, IMPROVED, OR DEMONSTRATED LESS THAN EXPECTED DECLINE IN FEV1 OR BODY MASS INDEX (BMI), OR 2) REDUCTION IN NUMBER OF PULMONARY EXACERBATIONS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MACITENTAN

**Products Affected**

- OPSUMIT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**MARGETUXIMAB-CMKB**

**Products Affected**

- MARGENZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MARIBAVIR

**Products Affected**

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MECASERMIN

**Products Affected**

- INCRELEX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. RENEWAL: IMPROVEMENT WHILE ON THERAPY (I.E., INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MECHLORETHAMINE

**Products Affected**

- VALCHLOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MEPOLIZUMAB

### Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: ASTHMA: 4 MO. CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA: 12 MO.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK,

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MIDOSTAURIN

**Products Affected**

- RYDAPT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MIFEPRISTONE

### Products Affected

- *mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (2 OR MORE TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (2 OR MORE TESTS TO CONFIRM).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE, ETC.), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MILTEFOSINE

---

**Products Affected**

- IMPAVIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MOMELOTINIB

**Products Affected**

- OJJAARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## MOSUNETUZUMAB-AXGB

### Products Affected

- LUNSUMIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NARCOLEPSY AGENTS

**Products Affected**

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# NAXITAMAB-GQGK

**Products Affected**

- DANYELZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NERATINIB

**Products Affected**

- NERLYNX

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NILOTINIB

### Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND TASIGNA IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NILOTINIB-DANZITEN

**Products Affected**

- DANZITEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NINTEDANIB

**Products Affected**

- OFEV

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) BASELINE FORCED VITAL CAPACITY (FVC) AT LEAST 50% OF PREDICTED VALUE. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 45% OF PREDICTED VALUE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
<b>Other Criteria</b>	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	TOXICITY, RECURRENT ASPIRATION), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ACTEMRA SUBQ. PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERD/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NIRAPARIB

**Products Affected**

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NIRAPARIB-ABIRATERONE

**Products Affected**

- AKEEGA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# NIROGACESTAT

**Products Affected**

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NITISINONE

### Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# NIVOLUMAB

**Products Affected**

- OPDIVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## NIVOLUMAB-HYALURONIDASE-NVHY

**Products Affected**

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**NIVOLUMAB-RELATLIMAB-RMBW**

**Products Affected**

- OPDUALAG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## NOGAPENDEKIN ALFA

**Products Affected**

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	40 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# OCRELIZUMAB

**Products Affected**

- OCREVUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OCRELIZUMAB-HYALURONIDASE-OCSQ

**Products Affected**

- OCREVUS ZUNOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# OFATUMUMAB-SQ

**Products Affected**

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OLANZAPINE/SAMIDORPHAN

### Products Affected

- LYBALVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SCHIZOPHRENIA, BIPOLAR I: PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST
Coverage Duration	12 MONTHS
Other Criteria	SCHIZOPHRENIA: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF LURASIDONE OR ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. BIPOLAR I: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OLAPARIB

### Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OLUTASIDENIB

**Products Affected**

- REZLIDHIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OMACETAXINE

**Products Affected**

- SYNRIBO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OMALIZUMAB

**Products Affected**

- XOLAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) ALLERGEN SPECIFIC IGE SERUM LEVEL OF AT LEAST 6 KUA/L TO AT LEAST ONE FOOD, OR POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
<b>Other Criteria</b>	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ONE PREFERRED AGENT: NUCALA, DUPIXENT, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. FOOD ALLERGY: 1) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 2) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, 2)</p>

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 3) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OSIMERTINIB

---

**Products Affected**

- TAGRISSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## OXANDROLONE

### Products Affected

- oxandrolone oral*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PACRITINIB

**Products Affected**

- VONJO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PALBOCICLIB

**Products Affected**

- IBRANCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ADVANCED OR METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE PREFERRED AGENTS, WHERE INDICATIONS ALIGN: KISQALI, VERZENIO.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PARATHYROID HORMONE

### Products Affected

- NATPARA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: 1) TRIAL OF OR CONTRAINDICATION TO CALCITRIOL, 2) HYPOPARATHYROIDISM IS NOT DUE TO A CALCIUM SENSING RECEPTOR (CSR) MUTATION, AND 3) HYPOPARATHYROIDISM IS NOT CONSIDERED ACUTE POST-SURGICAL HYPOPARATHYROIDISM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PASIREOTIDE DIASPARTATE

**Products Affected**

- SIGNIFOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# PAZOPANIB

**Products Affected**

- *pazopanib hcl*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEGFILGRASTIM - APGF

**Products Affected**

- NYVEPRIA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# PEGFILGRASTIM-NEULASTA ONPRO

**Products Affected**

- NEULASTA ONPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEGINTERFERON ALFA-2A

**Products Affected**

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
<b>Coverage Duration</b>	HEP B/HEP C: 48 WEEKS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEGVISOMANT

**Products Affected**

- SOMAVERT

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEMBROLIZUMAB

**Products Affected**

- KEYTRUDA INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEMIGATINIB

### Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PENICILLAMINE TABLET

### Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PEXIDARTINIB

### Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PIMAVANSERIN

**Products Affected**

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PIRFENIDONE

### Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50% AT BASELINE.
<b>Age Restrictions</b>	IPF: INITIAL: 18 YEARS OR OLDER.
<b>Prescriber Restrictions</b>	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PIRTOBRUTINIB

**Products Affected**

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# POMALIDOMIDE

## Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PONATINIB

**Products Affected**

- ICLUSIG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# POSACONAZOLE TABLET

**Products Affected**

- *posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PRALSETINIB

**Products Affected**

- GAVRETO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## PYRIMETHAMINE

### Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
Other Criteria	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## QUININE

**Products Affected**

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## QUIZARTINIB

**Products Affected**

- VANFLYTA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## REGORAFENIB

**Products Affected**

- STIVARGA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# RELUGOLIX

**Products Affected**

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## REPOTRECTINIB

**Products Affected**

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RESLIZUMAB

**Products Affected**

- CINQAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	ASTHMA: INITIAL: 4 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	ASTHMA: INITIAL: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, 3) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: FASENRA, NUCALA, DUPIXENT, AND 4) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA.

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	RENEWAL: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RETIFANLIMAB-DLWR

**Products Affected**

- ZYNYZ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## REVUMENIB

**Products Affected**

- REVUFORJ ORAL TABLET 110 MG,  
160 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIBOCICLIB

**Products Affected**

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIBOCICLIB-LETROZOLE

**Products Affected**

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIFAXIMIN

### Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
Other Criteria	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RILONACEPT

### Products Affected

- ARCALYST

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	<p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	CAPS: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS. DIRA: 1) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RILUZOLE

**Products Affected**

- TEGLUTIK
- TIGLUTIK SUSPENSION 50 MG/10ML ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIMEGEPANT

**Products Affected**

- NURTEC

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	<p>INITIAL: ACUTE MIGRAINE TREATMENT: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREVENTIVE MIGRAINE TREATMENTS: DIVALPROEX SODIUM, TOPIRAMATE, PROPRANOLOL, TIMOLOL. RENEWAL: ACUTE MIGRAINE TREATMENT: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.</p> <p>EPISODIC MIGRAINE PREVENTION: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION, AND 2) REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY,</p>

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIOCIGUAT

### Products Affected

- ADEMPAS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RIPRETINIB

---

**Products Affected**

- QINLOCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RISANKIZUMAB-RZAA

**Products Affected**

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: PSO, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## RITUXIMAB AND HYALURONIDASE HUMAN-SQ

### Products Affected

- RITUXAN HYCELA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RITUXIMAB-ABBS

### Products Affected

- TRUXIMA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RITUXIMAB-ARRX

**Products Affected**

- RIABNI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RHEUMATOID ARTHRITIS (RA): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RITUXIMAB-PVVR

### Products Affected

- RUXIENCE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	RA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA: 12 MO. CLL: 6 MO.
<b>Other Criteria</b>	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## ROPEGINTERFERON ALFA-2B-NJFT

**Products Affected**

- BESREMI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RUCAPARIB

**Products Affected**

- RUBRACA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## RUXOLITINIB

**Products Affected**

- JAKAFI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
<b>Other Criteria</b>	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# SAPROPTERIN

**Products Affected**

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
<b>Other Criteria</b>	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SECUKINUMAB IV

### Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS, NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: PSA, AS, NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SECUKINUMAB SQ

### Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: HS: 4 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS, NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. HS: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR HS OR OTHER IL-17 INHIBITORS FOR ANY INDICATION. RENEWAL: PSO, PSA, AS, NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ERA, HS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SELEXIPAG

### Products Affected

- UPTRAVI INTRAVENOUS
- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SELINEXOR

**Products Affected**

- XPOVIO (100 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 50  
MG
- XPOVIO (40 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (40 MG TWICE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (60 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 60  
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SELPERCATINIB

**Products Affected**

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SELUMETINIB

### Products Affected

- KOSELUGO ORAL CAPSULE 10 MG,  
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SILDENAFIL TABLET

### Products Affected

- sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SIPONIMOD

### Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): RENEWAL: DEMONSTRATED CLINICAL BENEFIT COMPARED TO PRE-TREATMENT BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## SIROLIMUS PROTEIN-BOUND

**Products Affected**

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SODIUM OXYBATE-XYREM

**Products Affected**

- *sodium oxybate*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY, AND 3) AGES 7 TO 17 YEARS: TRIAL, FAILURE OF, OR CONTRAINDICATION TO ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOFOSBUVIR/VELPATASVIR

**Products Affected**

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

### Products Affected

- VOSEVI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HCV RNA LEVEL WITHIN PAST 6 MONTHS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
<b>Other Criteria</b>	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOMATROPIN - NORDITROPIN

**Products Affected**

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
<b>Required Medical Information</b>	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), TURNER SYNDROME (TS), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ADULT GHD: GHD ALONE OR ASSOCIATED WITH MULTIPLE HORMONE DEFICIENCIES (HYPOPITUITARISM), AS A RESULT OF PITUITARY DISEASE, HYPOTHALAMIC DISEASE, SURGERY, RADIATION THERAPY, OR TRAUMA, OR FOR CONTINUATION OF THERAPY FROM CHILDHOOD ONSET GHD. PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. RENEWAL: PEDIATRIC GHD: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. ISS, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (I.E.,

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PWS: IMPROVEMENT IN BODY COMPOSITION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOMATROPIN - SEROSTIM

### Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 2) 7.5% UNINTENTIONAL WEIGHT LOSS OVER 6 MONTHS, 3) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 4) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 5) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 6) BMI LESS THAN 18.5 KG PER METER SQUARED.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 3 MONTHS.
<b>Other Criteria</b>	HIV/WASTING: INITIAL: 1) INADEQUATE RESPONSE TO ONE PREVIOUS THERAPY (E.G., MEGACE, APPETITE STIMULANTS, ANABOLIC STEROIDS). RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SONIDEGIB

**Products Affected**

- ODOMZO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## SORAFENIB

**Products Affected**

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOTATERCEPT-CSRK

**Products Affected**

- WINREVAIR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SOTORASIB

**Products Affected**

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## STIRIPENTOL

**Products Affected**

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## SUNITINIB

### Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB (GLEEVEC).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TADALAFIL - ADCIRCA, ALYQ

### Products Affected

- *alyq*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TADALAFIL-CIALIS

**Products Affected**

- *tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TALAZOPARIB

### Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# TALQUETAMAB-TGVS

**Products Affected**

- TALVEY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TARLATAMAB-DLLE

**Products Affected**

- IMDELLTRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# TAZEMETOSTAT

**Products Affected**

- TAZVERIK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TEBENTAFUSP-TEBN

**Products Affected**

- KIMMTRAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TECLISTAMAB-CQYV

**Products Affected**

- TECVAYLI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TELOTRISTAT

**Products Affected**

- XERMELO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# TEPOTINIB

**Products Affected**

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TERIPARATIDE

**Products Affected**

- TERIPARATIDE SUBCUTANEOUS  
SOLUTION PEN-INJECTOR 620  
MCG/2.48ML

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# TESTOSTERONE

**Products Affected**

- *testosterone gel 1.62 % transdermal*
- *testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TESTOSTERONE CYPIONATE

### Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TESTOSTERONE ENANTHATE

### Products Affected

- *testosterone enanthate intramuscular solution*
- XYOSTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
<b>Other Criteria</b>	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TETRABENAZINE

### Products Affected

- tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# THALIDOMIDE

**Products Affected**

- THALOMID

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TISLELIZUMAB-JSGR

**Products Affected**

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**TISOTUMAB VEDOTIN-TFTV**

**Products Affected**

- TIVDAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TIVOZANIB

**Products Affected**

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TOCILIZUMAB IV

### Products Affected

- ACTEMRA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

<b>PA Criteria</b>	<b>Criteria Details</b>
	MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TOCILIZUMAB SQ

### Products Affected

- ACTEMRA
- ACTEMRA ACTPEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS). RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. SSC-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TOFACITINIB

### Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PCJIA: 1) TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA, AS, PCJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TOPICAL TRETINOIN

**Products Affected**

- ALTRENO
- *tretinoin external cream*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TORIPALIMAB-TPZI

**Products Affected**

- LOQTORZI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TOVORAFENIB

**Products Affected**

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRAMADOL

**Products Affected**

- TRAMADOL HCL ORAL SOLUTION

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRAMETINIB SOLUTION

**Products Affected**

- MEKINIST ORAL SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRAMETINIB TABLET

### Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# TRASTUZUMAB-DKST

**Products Affected**

- OGIVRI

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRASTUZUMAB-DTTB

**Products Affected**

- ONTRUZANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## TRASTUZUMAB-HYALURONIDASE-OYSK

### Products Affected

- HERCEPTIN HYLECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRASTUZUMAB-PKRB

### Products Affected

- HERZUMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

# TRASTUZUMAB-QYYP

**Products Affected**

- TRAZIMERA

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TREMELIMUMAB-ACTL

### Products Affected

- IMJUDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
Other Criteria	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRIENTINE CAPSULE

### Products Affected

- *trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	WILSONS DISEASE: INITIAL: 1) LEIPZIG SCORE OF 4 OR GREATER, AND 2) TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TRIFLURIDINE/TIPIRACIL

**Products Affected**

- LONSURF ORAL TABLET 15-6.14 MG,  
20-8.19 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# TRIPTORELIN-TRELSTAR

## Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## TUCATINIB

**Products Affected**

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## UBROGEPANT

**Products Affected**

- UBRELVY

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## UPADACITINIB

**Products Affected**

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). ATOPIC DERMATITIS (AD): ATOPIC DERMATITIS COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR ATOPIC DERMATITIS AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PJA: 1) TRIAL OF OR CONTRAINDICATION TO ONE DMARD, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR, AND 3) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITORS FOR ANY INDICATION. UC, CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. AS, NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG), AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITOR FOR ANY INDICATION. PSA, AS, NR-AXSPA, PJA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. UC, CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## USTEKINUMAB

**Products Affected**

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. RENEWAL: PSA, PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## USTEKINUMAB IV

**Products Affected**

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	2 MONTHS
<b>Other Criteria</b>	CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VALBENZINE

**Products Affected**

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VANDETANIB

**Products Affected**

- CAPRELSA ORAL TABLET 100 MG,  
300 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# VANZACAFITOR-TEZACAFITOR- DEUTIVACAFITOR

**Products Affected**

- ALYFTREK ORAL TABLET 10-50-125  
MG, 4-20-50 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VEMURAFENIB

**Products Affected**

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VENETOCLAX

**Products Affected**

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VERICIGUAT

### Products Affected

- VERQUVO

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL/RENEWAL:12 MONTHS.
<b>Other Criteria</b>	HEART FAILURE (HF): INITIAL: 1) NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIGUAT, OR PDE-5 INHIBITORS, 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED SGLT-2 INHIBITOR, AND 3) TRIAL OF OR CONTRAINDICATION TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (I.E., BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (I.E., SPIRONOLACTONE, EPLERENONE). RENEWAL: NO CONCURRENT USE WITH LONG-ACTING NITRATES OR NITRIC OXIDE DONORS, RIOCIGUAT, OR PDE-5 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C

Formulary ID: 25265 v10

Last Updated: 02/19/2025

Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

# VIGABATRIN

**Products Affected**

- *vigabatrín*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CPS: TRIAL OF OR CONTRAINDICATION TO TWO ANTIEPILEPTIC AGENTS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VISMODEGIB

**Products Affected**

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VORASIDENIB

---

**Products Affected**

- VORANIGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025



Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## VORICONAZOLE SUSPENSION

**Products Affected**

- *voriconazole oral suspension reconstituted*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
<b>Other Criteria</b>	CANDIDA INFECTIONS: 1) TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE, AND 2) UNABLE TO SWALLOW TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

**ZANIDATAMAB-HRII**

**Products Affected**

- ZIIHERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ZANUBRUTINIB

### Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## ZENOCUTUZUMAB-ZBCO

**Products Affected**

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
 Prior Authorization Criteria

## ZOLBETUXIMAB-CLZB

**Products Affected**

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1119\_PA25\_C  
 Formulary ID: 25265 v10  
 Last Updated: 02/19/2025  
 Effective: 03/01/2025

Valor Health Plan 2025 Formulary  
Prior Authorization Criteria

## ZURANOLONE

**Products Affected**

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 DAYS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

H1119\_PA25\_C  
Formulary ID: 25265 v10  
Last Updated: 02/19/2025  
Effective: 03/01/2025

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

### INDEX

#### A

abiraterone acetate ..... 7  
 ABOUTTIME PEN NEEDLE 30G X 8 MM  
 ..... 148, 166  
 ABOUTTIME PEN NEEDLE 31G X 5 MM  
 ..... 148, 166  
 ABOUTTIME PEN NEEDLE 31G X 8 MM  
 ..... 148, 166  
 ABOUTTIME PEN NEEDLE 32G X 4 MM  
 ..... 148, 166  
 ACTEMRA..... 330, 331, 332, 333  
 ACTEMRA ACTPEN ..... 332, 333  
 ACTHAR ..... 67  
 ACTHAR GEL SUBCUTANEOUS AUTO-  
 INJECTOR 40 UNIT/0.5ML, 80  
 UNIT/ML..... 67  
 ACTIMMUNE..... 170  
 ADEMPAS ..... 275, 276  
 ADVOCATE INSULIN PEN NEEDLE 32G  
 X 4 MM..... 148, 166  
 ADVOCATE INSULIN PEN NEEDLES  
 29G X 12.7MM..... 148, 166  
 ADVOCATE INSULIN PEN NEEDLES  
 31G X 5 MM..... 148, 166  
 ADVOCATE INSULIN PEN NEEDLES  
 31G X 8 MM..... 148, 166  
 ADVOCATE INSULIN PEN NEEDLES  
 33G X 4 MM..... 148, 166  
 ADVOCATE INSULIN SYRINGE 29G X  
 1/2 ..... 148, 166  
 ADVOCATE INSULIN SYRINGE 30G X  
 5/16 ..... 148, 166  
 ADVOCATE INSULIN SYRINGE 31G X  
 5/16 ..... 148, 166  
 AJOVY ..... 122  
 AKEEGA ..... 217  
 ALCOHOL PREP PAD..... 148, 166  
 ALCOHOL PREP PAD 70 %..... 148, 166  
 ALCOHOL PREP PADS PAD 70 % .... 148,  
 166  
 ALCOHOL SWABS PAD..... 148, 166  
 ALCOHOL SWABS PAD 70 % .... 148, 166  
 ALCOHOL SWABSTICK PAD .... 148, 166

ALCOHOL SWABSTICK PAD 70 % .. 148,  
 166  
 ALECENSA..... 15  
 ALTRENO..... 336  
 ALUNBRIG ORAL TABLET 180 MG, 30  
 MG, 90 MG..... 51  
 ALUNBRIG ORAL TABLET THERAPY  
 PACK..... 51  
 ALVAIZ..... 96  
 ALYFTREK ORAL TABLET 10-50-125  
 MG, 4-20-50 MG ..... 360  
 alyq..... 311  
 ANKTIVA ..... 223  
 APLICARE ALCOHOL SWABSTICK  
 PAD 70 % ..... 148, 166  
 AQ INSULIN SYRINGE 31G X 5/16... 148,  
 166  
 AQINJECT PEN NEEDLE 31G X 5 MM  
 ..... 148, 166  
 AQINJECT PEN NEEDLE 32G X 4 MM  
 ..... 148, 166  
 ARCALYST ..... 270, 271  
 ARIKAYCE..... 17  
 armodafinil..... 209  
 ASSURE ID DUO PRO PEN NEEDLES  
 31G X 5 MM..... 148, 166  
 ASSURE ID INSULIN SAFETY SYR 29G  
 X 1/2..... 148, 166  
 ASSURE ID INSULIN SAFETY SYR 31G  
 X 15/64..... 148, 166  
 ASSURE ID PRO PEN NEEDLES 30G X 5  
 MM ..... 148, 166  
 AUGTYRO ORAL CAPSULE 160 MG, 40  
 MG ..... 262  
 AUM ALCOHOL PREP PADS PAD 70 %  
 ..... 148, 166  
 AUM INSULIN SAFETY PEN NEEDLE  
 31G X 4 MM..... 148, 166  
 AUM INSULIN SAFETY PEN NEEDLE  
 31G X 5 MM..... 148, 166  
 AUM MINI INSULIN PEN NEEDLE 32G  
 X 4 MM..... 148, 166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

AUM MINI INSULIN PEN NEEDLE 32G X 5 MM..... 148, 166	BD INSULIN SYRINGE 25G X 1. 149, 166
AUM MINI INSULIN PEN NEEDLE 32G X 6 MM..... 148, 166	BD INSULIN SYRINGE 25G X 5/8..... 149, 166
AUM MINI INSULIN PEN NEEDLE 32G X 8 MM..... 148, 166	BD INSULIN SYRINGE 26G X 1/2..... 149, 166
AUM MINI INSULIN PEN NEEDLE 33G X 4 MM..... 148, 166	BD INSULIN SYRINGE 27.5G X 5/8.. 149, 166
AUM MINI INSULIN PEN NEEDLE 33G X 5 MM..... 149, 166	BD INSULIN SYRINGE 27G X 1/2..... 149, 166
AUM MINI INSULIN PEN NEEDLE 33G X 6 MM..... 149, 166	BD INSULIN SYRINGE 29G X 1/2..... 149, 166
AUM PEN NEEDLE 32G X 4 MM 149, 166	BD INSULIN SYRINGE HALF-UNIT 31G X 5/16..... 149, 166
AUM PEN NEEDLE 32G X 5 MM 149, 166	BD INSULIN SYRINGE MICROFINE 27G X 5/8..... 149, 166
AUM PEN NEEDLE 32G X 6 MM 149, 166	BD INSULIN SYRINGE MICROFINE 28G X 1/2..... 149, 166
AUM PEN NEEDLE 33G X 4 MM 149, 166	BD INSULIN SYRINGE U/F 30G X 1/2 ..... 149, 166
AUM PEN NEEDLE 33G X 5 MM 149, 166	BD INSULIN SYRINGE U-100 1 ML . 149, 166
AUM PEN NEEDLE 33G X 6 MM 149, 166	BD INSULIN SYRINGE U-500 31G X 6MM 0.5 ML ..... 149, 166
AUM READYGARD DUO PEN NEEDLE 32G X 4 MM..... 149, 166	BD INSULIN SYRINGE ULTRAFINE 29G X 1/2..... 149, 166
AUM SAFETY PEN NEEDLE 31G X 4 MM ..... 149, 166	BD INSULIN SYRINGE ULTRAFINE 30G X 1/2..... 149, 166
AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG ..... 81	BD PEN NEEDLE MICRO U/F 32G X 6 MM ..... 149, 166
AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG ..... 81	BD PEN NEEDLE MINI U/F 31G X 5 MM ..... 149, 166
AUSTEDO XR PATIENT TITRATION . 81	BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM..... 149, 166
AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT..... 167	BD PEN NEEDLE NANO U/F 32G X 4 MM (OTC)..... 149, 166
AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT..... 167	BD PEN NEEDLE NANO U/F 32G X 4 MM (RX) ..... 149, 166
AYVAKIT ..... 31	BD PEN NEEDLE ORIGINAL U/F 29G X 12.7MM ..... 149, 166
<b>B</b>	BD PEN NEEDLE SHORT U/F 31G X 8 MM ..... 149, 166
BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG..... 106	BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2..... 149, 166
BD AUTOSHIELD 29G X 5MM... 149, 166	BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16..... 149, 166
BD AUTOSHIELD 29G X 8MM... 149, 166	
BD AUTOSHIELD DUO 30G X 5 MM 149, 166	
BD ECLIPSE SYRINGE 30G X 1/2..... 149, 166	
BD INSULIN SYR ULTRAFINE II 31G X 5/16 ..... 149, 166	



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64.....	149, 150, 166	CAREFINE PEN NEEDLES 31G X 6 MM .....	150, 166
BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16.....	150, 166	CAREFINE PEN NEEDLES 31G X 8 MM .....	150, 166
BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8.....	150, 166	CAREFINE PEN NEEDLES 32G X 4 MM .....	150, 166
BD SAFETY-LOK INSULIN SYRINGE 29G X 1/2.....	149, 166	CAREFINE PEN NEEDLES 32G X 5 MM .....	150, 166
BD SWAB SINGLE USE REGULAR PAD .....	150, 166	CAREFINE PEN NEEDLES 32G X 6 MM .....	150, 166
BD SWABS SINGLE USE BUTTERFLY PAD.....	150, 166	CAREONE INSULIN SYRINGE 30G X 1/2 .....	150, 166
BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64.....	150, 166	CAREONE INSULIN SYRINGE 31G X 5/16 .....	150, 166
BD VEO INSULIN SYRINGE U/F 31G X 15/64 .....	150, 166	CARETOUCH ALCOHOL PREP PAD 70 % .....	150, 166
BENDAMUSTINE HCL INTRAVENOUS SOLUTION.....	39	CARETOUCH INSULIN SYRINGE 28G X 5/16 .....	150, 166
bendamustine hcl intravenous solution reconstituted.....	39	CARETOUCH INSULIN SYRINGE 29G X 5/16 .....	150, 166
BENDEKA .....	39	CARETOUCH INSULIN SYRINGE 30G X 5/16 .....	150, 166
BENLYSTA SUBCUTANEOUS.....	36	CARETOUCH INSULIN SYRINGE 31G X 5/16 .....	150, 166
BESREMI .....	284	CARETOUCH PEN NEEDLES 29G X 12MM .....	150, 166
betaine .....	42	CARETOUCH PEN NEEDLES 31G X 5 MM .....	150, 166
BETASERON SUBCUTANEOUS KIT	168	CARETOUCH PEN NEEDLES 31G X 6 MM .....	150, 166
bexarotene .....	46	CARETOUCH PEN NEEDLES 31G X 8 MM .....	150, 166
BIZENGRI (750 MG DOSE) .....	370	CARETOUCH PEN NEEDLES 32G X 4 MM .....	150, 166
bortezomib injection .....	48	CARETOUCH PEN NEEDLES 32G X 5 MM .....	150, 166
BORUZU .....	48	CARETOUCH PEN NEEDLES 33G X 4 MM .....	150, 166
bosentan .....	49	carglumic acid oral tablet soluble .....	58
BOSULIF ORAL CAPSULE 100 MG, 50 MG .....	50	CAYSTON.....	34
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	50	CIMZIA (2 SYRINGE) .....	60, 62
BRAFTOVI ORAL CAPSULE 75 MG ...	99	CIMZIA SUBCUTANEOUS KIT 2 X 200 MG .....	60, 62
BRUKINSA .....	369	CINQAIR.....	263, 264
<b>C</b>		CLEVER CHOICE COMFORT EZ 29G X 12MM .....	150, 166
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG.....	54		
CALQUENCE .....	9		
CAPRELSA ORAL TABLET 100 MG, 300 MG .....	359		
CAREFINE PEN NEEDLES 29G X 12MM .....	150, 166		
CAREFINE PEN NEEDLES 30G X 8 MM .....	150, 166		

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

CLEVER CHOICE COMFORT EZ 33G X 4 MM .....	150, 166	COMFORT EZ PEN NEEDLES 33G X 5 MM .....	151, 166
CLICKFINE PEN NEEDLES 31G X 6 MM .....	150, 166	COMFORT EZ PEN NEEDLES 33G X 6 MM .....	151, 166
CLICKFINE PEN NEEDLES 31G X 8 MM .....	151, 166	COMFORT EZ PEN NEEDLES 33G X 8 MM .....	151, 166
CLICKFINE PEN NEEDLES 32G X 4 MM .....	151, 166	COMFORT EZ PRO PEN NEEDLES 30G X 8 MM.....	151, 166
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG .....	53	COMFORT EZ PRO PEN NEEDLES 31G X 4 MM.....	151, 166
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG .....	53	COMFORT EZ PRO PEN NEEDLES 31G X 5 MM.....	151, 166
COMETRIQ (60 MG DAILY DOSE).....	53	COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM.....	151, 166
COMFORT ASSIST INSULIN SYRINGE 29G X 1/2.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM.....	151, 166
COMFORT ASSIST INSULIN SYRINGE 31G X 5/16.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 28G X 1/2.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 29G X 1/2.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 30G X 1/2.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 30G X 5/16.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 31G X 15/64.....	151, 166	COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM.....	151, 166
COMFORT EZ INSULIN SYRINGE 31G X 5/16.....	151, 166	COPIKTRA.....	91
COMFORT EZ PEN NEEDLES 31G X 5 MM .....	151, 166	COSENTYX (300 MG DOSE).....	290, 291
COMFORT EZ PEN NEEDLES 31G X 6 MM .....	151, 166	COSENTYX INTRAVENOUS.....	288, 289
COMFORT EZ PEN NEEDLES 31G X 8 MM .....	151, 166	COSENTYX SENSOREADY (300 MG) .....	290, 291
COMFORT EZ PEN NEEDLES 31G X 4 MM .....	151, 166	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML.....	290, 291
COMFORT EZ PEN NEEDLES 32G X 4 MM .....	151, 166	COSENTYX UNOREADY .....	290, 291
COMFORT EZ PEN NEEDLES 32G X 5 MM .....	151, 166	COTELLIC .....	66
COMFORT EZ PEN NEEDLES 32G X 6 MM .....	151, 166	CURITY ALCOHOL PREPS PAD 70 % .....	151, 166
COMFORT EZ PEN NEEDLES 32G X 8 MM .....	151, 166	CURITY ALL PURPOSE SPONGES PAD 2.....	151, 166
COMFORT EZ PEN NEEDLES 33G X 4 MM .....	151, 166	CURITY GAUZE PAD 2 .....	152, 166
		CURITY GAUZE SPONGE PAD 2.....	152, 166
		CURITY SPONGES PAD 2.....	152, 166

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

CVS GAUZE PAD 2 .....	152, 166	DROPLET INSULIN SYRINGE 30G X	
CVS GAUZE STERILE PAD 2 .....	152, 166	5/16 .....	152, 166
<b>D</b>		DROPLET INSULIN SYRINGE 31G X	
dalfampridine er .....	73	15/64 .....	152, 166
DANYELZA .....	210	DROPLET INSULIN SYRINGE 31G X	
DANZITEN .....	213	5/16 .....	152, 166
dasatinib oral tablet 100 mg, 140 mg, 20 mg,		DROPLET MICRON 34G X 3.5 MM...	152,
50 mg, 70 mg, 80 mg .....	75	166	
DATROWAY .....	76	DROPLET PEN NEEDLES 29G X 10MM	
DAURISMO ORAL TABLET 100 MG, 25		.....	152, 166
MG .....	129	DROPLET PEN NEEDLES 29G X 12MM	
deferasirox granules .....	78, 79	.....	152, 166
deferasirox oral tablet .....	78, 79	DROPLET PEN NEEDLES 30G X 8 MM	
DERMACEA GAUZE SPONGE PAD 2		.....	152, 166
.....	152, 166	DROPLET PEN NEEDLES 31G X 5 MM	
DERMACEA IV DRAIN SPONGES PAD		.....	152, 166
2.....	152, 166	DROPLET PEN NEEDLES 31G X 6 MM	
DERMACEA NON-WOVEN SPONGES		.....	152, 166
PAD 2.....	152, 166	DROPLET PEN NEEDLES 31G X 8 MM	
DERMACEA TYPE VII GAUZE PAD 2		.....	152, 166
.....	152, 166	DROPLET PEN NEEDLES 32G X 4 MM	
DIACOMIT ORAL CAPSULE 250 MG,		.....	152, 166
500 MG .....	309	DROPLET PEN NEEDLES 32G X 5 MM	
DIACOMIT ORAL PACKET 250 MG, 500		.....	152, 166
MG .....	309	DROPLET PEN NEEDLES 32G X 6 MM	
DIATHRIVE PEN NEEDLE 31G X 5 MM		.....	152, 166
.....	152, 166	DROPLET PEN NEEDLES 32G X 8 MM	
DIATHRIVE PEN NEEDLE 31G X 6 MM		.....	152, 166
.....	152, 166	DROPSAFE ALCOHOL PREP PAD 70 %	
DIATHRIVE PEN NEEDLE 31G X 8 MM		.....	152, 166
.....	152, 166	DROPSAFE SAFETY PEN NEEDLES 31G	
DIATHRIVE PEN NEEDLE 32G X 4 MM		X 5 MM.....	152, 166
.....	152, 166	DROPSAFE SAFETY PEN NEEDLES 31G	
diclofenac sodium external solution 2 % ..	82	X 6 MM.....	152, 166
dimethyl fumarate oral capsule delayed		DROPSAFE SAFETY PEN NEEDLES 31G	
release 120 mg, 240 mg .....	83	X 8 MM.....	152, 166
dimethyl fumarate starter pack oral capsule		DROPSAFE SAFETY SYRINGE/NEEDLE	
delayed release therapy pack .....	83	29G X 1/2.....	152, 166
dronabinol .....	86	DROPSAFE SAFETY SYRINGE/NEEDLE	
DROPLET INSULIN SYRINGE 29G X 1/2		31G X 15/64.....	152, 166
.....	152, 166	DROPSAFE SAFETY SYRINGE/NEEDLE	
DROPLET INSULIN SYRINGE 30G X 1/2		31G X 5/16.....	152, 153, 166
.....	152, 166	droxidopa .....	87
DROPLET INSULIN SYRINGE 30G X		DRUG MART ULTRA COMFORT SYR	
15/64 .....	152, 166	29G X 1/2.....	153, 166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

DRUG MART ULTRA COMFORT SYR  
30G X 5/16..... 153, 166  
DRUG MART UNIFINE PENTIPS 31G X  
5 MM ..... 153, 166  
DUPIXENT SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR .... 88, 90  
DUPIXENT SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE . 88,  
90

#### E

EASY COMFORT ALCOHOL PADS PAD  
..... 153, 166  
EASY COMFORT INSULIN SYRINGE  
30G X 1/2..... 153, 166  
EASY COMFORT INSULIN SYRINGE  
30G X 5/16..... 153, 166  
EASY COMFORT INSULIN SYRINGE  
31G X 1/2..... 153, 166  
EASY COMFORT INSULIN SYRINGE  
31G X 5/16..... 153, 166  
EASY COMFORT INSULIN SYRINGE  
32G X 5/16..... 153, 166  
EASY COMFORT PEN NEEDLES 31G X  
5 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 31G X  
6 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 31G X  
8 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 32G X  
4 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 33G X  
4 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 33G X  
5 MM ..... 153, 166  
EASY COMFORT PEN NEEDLES 33G X  
6 MM ..... 153, 166  
EASY GLIDE PEN NEEDLES 33G X 4  
MM ..... 153, 166  
EASY TOUCH ALCOHOL PREP  
MEDIUM PAD 70 %..... 153, 166  
EASY TOUCH FLIPLOCK INSULIN SY  
29G X 1/2..... 153, 166  
EASY TOUCH FLIPLOCK INSULIN SY  
30G X 1/2..... 153, 166  
EASY TOUCH FLIPLOCK INSULIN SY  
30G X 5/16..... 153, 166

EASY TOUCH FLIPLOCK INSULIN SY  
31G X 5/16..... 153, 166  
EASY TOUCH FLIPLOCK SAFETY SYR  
27G X 1/2..... 153, 166  
EASY TOUCH INSULIN BARRELS 1ML  
..... 153, 166  
EASY TOUCH INSULIN SAFETY SYR  
29G X 1/2..... 153, 166  
EASY TOUCH INSULIN SAFETY SYR  
30G X 1/2..... 153, 166  
EASY TOUCH INSULIN SAFETY SYR  
30G X 5/16..... 153, 166  
EASY TOUCH INSULIN SYRINGE 27G  
X 1/2..... 153, 166  
EASY TOUCH INSULIN SYRINGE 27G  
X 5/8..... 153, 166  
EASY TOUCH INSULIN SYRINGE 28G  
X 1/2..... 153, 166  
EASY TOUCH INSULIN SYRINGE 29G  
X 1/2..... 153, 166  
EASY TOUCH INSULIN SYRINGE 30G  
X 1/2..... 154, 166  
EASY TOUCH INSULIN SYRINGE 30G  
X 5/16..... 154, 166  
EASY TOUCH INSULIN SYRINGE 31G  
X 5/16..... 154, 166  
EASY TOUCH PEN NEEDLES 29G X  
12MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 30G X 5  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 30G X 6  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 30G X 8  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 31G X 5  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 31G X 6  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 31G X 8  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 32G X 4  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 32G X 5  
MM ..... 154, 166  
EASY TOUCH PEN NEEDLES 32G X 6  
MM ..... 154, 166

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	154, 166	EPIDIOLEX.....	55
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	154, 166	EPKINLY .....	103
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	154, 166	EQL ALCOHOL SWABS PAD 70 %... 154,	166
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	154, 166	EQL GAUZE PAD 2 .....	154, 166
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	154, 166	EQL INSULIN SYRINGE 30G X 5/16. 154,	166
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	154, 166	ERBITUX .....	63
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	154, 166	ERIVEDGE.....	365
ELIGARD .....	185	ERLEADA ORAL TABLET 240 MG, 60	MG .....
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76	MG/1.9ML .....	erlotinib hcl oral tablet 100 mg, 150 mg, 25	mg .....
EMBRACE PEN NEEDLES 29G X 12MM .....	154, 166	mg .....	107
EMBRACE PEN NEEDLES 30G X 5 MM .....	154, 166	everolimus oral tablet 10 mg, 2.5 mg, 5 mg,	7.5 mg .....
EMBRACE PEN NEEDLES 30G X 8 MM .....	154, 166	111	
EMBRACE PEN NEEDLES 31G X 5 MM .....	154, 166	everolimus oral tablet soluble .....	112
EMBRACE PEN NEEDLES 31G X 6 MM .....	154, 166	EXEL COMFORT POINT PEN NEEDLE 29G X 12MM.....	154, 166
EMBRACE PEN NEEDLES 31G X 8 MM .....	154, 166	<b>F</b>	
EMBRACE PEN NEEDLES 32G X 4 MM .....	154, 166	FASENRA .....	40, 41
EMGALITY .....	125	FASENRA PEN.....	40, 41
EMGALITY (300 MG DOSE) .....	125	fentanyl citrate buccal lozenge on a handle .....	116
ENBREL MINI.....	109, 110	FIFTY50 PEN NEEDLES 32G X 6 MM .....	154, 166
ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML.....	109, 110	fingolimod hcl.....	120
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE .....	109, 110	FINTEPLA.....	115
ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED.....	109, 110	FOTIVDA.....	329
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR	109, 110	FREESTYLE PRECISION INS SYR 30G X 5/16 .....	154, 166
EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG.....	300	FREESTYLE PRECISION INS SYR 31G X 5/16 .....	154, 166
EPCLUSA ORAL TABLET.....	300	FRUZAQLA ORAL CAPSULE 1 MG, 5 MG .....	123
		FYARRO .....	298
		<b>G</b>	
		GAUZE PADS PAD 2.....	154, 166
		GAUZE TYPE VII MEDI-PAK PAD 2	154,
		166	
		GAVRETO .....	256
		gefitinib.....	127
		GILOTRIF .....	14
		glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml	130
		glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml.....	130

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

GLOBAL ALCOHOL PREP EASE154, 166	GOODSENSE ALCOHOL SWABS PAD
GLOBAL EASE INJECT PEN NEEDLES	70 % ..... 155, 166
29G X 12MM..... 155, 166	<b>H</b>
GLOBAL EASE INJECT PEN NEEDLES	HAEGARDA SUBCUTANEOUS
31G X 5 MM..... 155, 166	SOLUTION RECONSTITUTED 2000
GLOBAL EASE INJECT PEN NEEDLES	UNIT, 3000 UNIT ..... 52
31G X 8 MM..... 155, 166	HARVONI ORAL PACKET 33.75-150
GLOBAL EASE INJECT PEN NEEDLES	MG, 45-200 MG ..... 179
32G X 4 MM..... 155, 166	HARVONI ORAL TABLET ..... 179
GLOBAL EASY GLIDE INSULIN SYR	HEALTHWISE INSULIN SYR/NEEDLE
31G X 15/64..... 155, 166	30G X 5/16..... 155, 156, 166
GLOBAL INJECT EASE INSULIN SYR	HEALTHWISE INSULIN SYR/NEEDLE
28G X 1/2..... 155, 166	31G X 5/16..... 156, 166
GLOBAL INJECT EASE INSULIN SYR	HEALTHWISE MICRON PEN NEEDLES
29G X 1/2..... 155, 166	32G X 4 MM..... 156, 166
GLOBAL INJECT EASE INSULIN SYR	HEALTHWISE SHORT PEN NEEDLES
30G X 1/2..... 155, 166	31G X 5 MM..... 156, 166
GLOBAL INJECT EASE INSULIN SYR	HEALTHWISE SHORT PEN NEEDLES
30G X 5/16..... 155, 166	31G X 8 MM..... 156, 166
GLUCOPRO INSULIN SYRINGE 30G X	HEALTHY ACCENTS UNIFINE PENTIP
1/2 ..... 155, 166	29G X 12MM..... 156, 166
GLUCOPRO INSULIN SYRINGE 30G X	HEALTHY ACCENTS UNIFINE PENTIP
5/16 ..... 155, 166	31G X 5 MM..... 156, 166
GLUCOPRO INSULIN SYRINGE 31G X	HEALTHY ACCENTS UNIFINE PENTIP
5/16 ..... 155, 166	31G X 6 MM..... 156, 166
GNP ALCOHOL SWABS PAD..... 155, 166	HEALTHY ACCENTS UNIFINE PENTIP
GNP INSULIN SYRINGE 28G X 1/2 .. 155,	31G X 8 MM..... 156, 166
166	HEALTHY ACCENTS UNIFINE PENTIP
GNP INSULIN SYRINGE 29G X 1/2 .. 155,	32G X 4 MM..... 156, 166
166	H-E-B INCONTROL ALCOHOL PAD 155,
GNP INSULIN SYRINGE 30G X 5/16 155,	166
166	H-E-B INCONTROL PEN NEEDLES 29G
GNP INSULIN SYRINGES 29GX1/2 .. 155,	X 12MM..... 155, 166
166	H-E-B INCONTROL PEN NEEDLES 31G
GNP INSULIN SYRINGES 30G X 5/16	X 5 MM..... 155, 166
..... 155, 166	H-E-B INCONTROL PEN NEEDLES 31G
GNP INSULIN SYRINGES 30GX5/16 155,	X 6 MM..... 155, 166
166	H-E-B INCONTROL PEN NEEDLES 31G
GNP INSULIN SYRINGES 31GX5/16 155,	X 8 MM..... 155, 166
166	H-E-B INCONTROL PEN NEEDLES 32G
GNP STERILE GAUZE PAD 2..... 155, 166	X 4 MM..... 155, 166
GNP ULTRA COM INSULIN SYRINGE	HERCEPTIN HYLECTA..... 344
29G X 1/2..... 155, 166	HERZUMA..... 345
GNP ULTRA COM INSULIN SYRINGE	HM STERILE PADS PAD 2..... 156, 166
30G X 5/16..... 155, 166	HM ULTICARE INSULIN SYRINGE 30G
	X 1/2..... 156, 166

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

HM ULTICARE INSULIN SYRINGE 31G X 5/16.....	156, 166	INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM.....	156, 166
HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM.....	156, 166	INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM.....	156, 166
HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 12, 13	INCRELEX.....	200
HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML.....	11, 12, 13	infiximab.....	146, 147
HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 12, 13	INGREZZA ORAL CAPSULE.....	358
HUMIRA-PED<40KG CROHNS STARTER.....	11, 12, 13	INGREZZA ORAL CAPSULE SPRINKLE.....	358
HUMIRA-PED>/=40KG CROHNS STARTER.....	11, 12, 13	INGREZZA ORAL CAPSULE THERAPY PACK.....	358
HUMIRA-PED>/=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 12, 13	INLYTA ORAL TABLET 1 MG, 5 MG..	32
HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 12, 13	INQOVI.....	77
HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT.....	11, 12, 13	INREBIC.....	114
<b>I</b>		INSULIN SYRINGE 29G X 1/2 ....	156, 166
IBRANCE.....	237	INSULIN SYRINGE 30G X 5/16 ..	156, 166
icatibant acetate subcutaneous solution prefilled syringe.....	139	INSULIN SYRINGE 31G X 5/16 ..	156, 166
ICLUSIG.....	254	INSULIN SYRINGE/NEEDLE 27G X 1/2.....	156, 166
IDHIFA.....	98	INSULIN SYRINGE/NEEDLE 28G X 1/2.....	156, 166
imatinib mesylate oral tablet 100 mg, 400 mg.....	141	INSULIN SYRINGE-NEEDLE U-100 27G X 1/2.....	156, 166
IMBRUVICA ORAL CAPSULE 140 MG, 70 MG.....	138	INSULIN SYRINGE-NEEDLE U-100 28G X 1/2.....	156, 166
IMBRUVICA ORAL SUSPENSION.....	138	INSULIN SYRINGE-NEEDLE U-100 30G X 5/16.....	156, 166
IMBRUVICA ORAL TABLET.....	138	INSULIN SYRINGE-NEEDLE U-100 31G X 1/4.....	156, 166
IMDELLTRA.....	315	INSULIN SYRINGE-NEEDLE U-100 31G X 5/16.....	156, 166
IMJUDO.....	347	INSUPEN PEN NEEDLES 31G X 5 MM.....	156, 166
IMKELDI.....	142	INSUPEN PEN NEEDLES 32G X 4 MM.....	156, 166
IMPAVIDO.....	206	INSUPEN PEN NEEDLES 33G X 4 MM.....	156, 166
INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM.....	156, 166	INSUPEN ULTRAFIN 29G X 12MM..	156, 166
		INSUPEN ULTRAFIN 31G X 8 MM...	156, 166
		ITOVEBI ORAL TABLET 3 MG, 9 MG.....	144
		IWILFIN.....	92
		<b>J</b>	
		J & J GAUZE PAD 2.....	156, 166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

JAKAFI.....	286	LEADER UNIFINE PENTIPS 31G X 5	
javygtor oral tablet .....	287	MM .....	157, 166
JAYPIRCA ORAL TABLET 100 MG, 50		LEADER UNIFINE PENTIPS 32G X 4	
MG .....	252	MM .....	157, 166
JEMPERLI.....	85	LEADER UNIFINE PENTIPS PLUS 31G	
<b>K</b>		X 5 MM.....	157, 166
KALYDECO.....	172	LEADER UNIFINE PENTIPS PLUS 31G	
KENDALL HYDROPHILIC FOAM		X 8 MM.....	157, 166
DRESS PAD 2 .....	156, 166	lenalidomide.....	180
KENDALL HYDROPHILIC FOAM PLUS		LENVIMA (10 MG DAILY DOSE) .....	181
PAD 2.....	156, 166	LENVIMA (12 MG DAILY DOSE) .....	181
KERENDIA .....	119	LENVIMA (14 MG DAILY DOSE) .....	181
KESIMPTA.....	226	LENVIMA (18 MG DAILY DOSE) .....	181
KEYTRUDA INTRAVENOUS		LENVIMA (20 MG DAILY DOSE) .....	181
SOLUTION.....	245	LENVIMA (24 MG DAILY DOSE) .....	181
KIMMTRAK .....	317	LENVIMA (4 MG DAILY DOSE) .....	181
KINERET SUBCUTANEOUS SOLUTION		LENVIMA (8 MG DAILY DOSE) .....	181
PREFILLED SYRINGE .....	19, 20	LEUPROLIDE ACETATE (3 MONTH)	184
KINRAY INSULIN SYRINGE 29G X 1/2		leuprolide acetate injection .....	183
.....	156, 166	l-glutamine oral packet .....	189
KISQALI (200 MG DOSE).....	267	lidocaine external ointment 5 % .....	190
KISQALI (400 MG DOSE).....	267	lidocaine external patch 5 % .....	191
KISQALI (600 MG DOSE).....	267	lidocaine-prilocaine external cream .....	192
KISQALI FEMARA (200 MG DOSE) ..	268	lidocan.....	191
KISQALI FEMARA (400 MG DOSE) ..	268	LITETOUCH INSULIN SYRINGE 28G X	
KISQALI FEMARA (600 MG DOSE) ..	268	1/2 .....	157, 166
KMART VALU INSULIN SYRINGE 29G		LITETOUCH INSULIN SYRINGE 29G X	
U-100 1 ML .....	156, 166	1/2 .....	157, 166
KMART VALU INSULIN SYRINGE 30G		LITETOUCH INSULIN SYRINGE 30G X	
U-100 0.3 ML .....	156, 166	5/16 .....	157, 166
KMART VALU INSULIN SYRINGE 30G		LITETOUCH INSULIN SYRINGE 31G X	
U-100 1 ML .....	156, 166	5/16 .....	157, 166
KOSELUGO ORAL CAPSULE 10 MG, 25		LITETOUCH PEN NEEDLES 29G X	
MG .....	295	12.7MM .....	157, 166
KRAZATI.....	10	LITETOUCH PEN NEEDLES 31G X 5	
KROGER PEN NEEDLES 29G X 12MM		MM .....	157, 166
.....	156, 166	LITETOUCH PEN NEEDLES 31G X 6	
KROGER PEN NEEDLES 31G X 8 MM		MM .....	157, 166
.....	157, 166	LITETOUCH PEN NEEDLES 31G X 8	
KYNMOBI .....	22	MM .....	157, 166
KYNMOBI TITRATION KIT .....	22	LITETOUCH PEN NEEDLES 32G X 4	
<b>L</b>		MM .....	157, 166
LANREOTIDE ACETATE.....	175	LIVTENCITY.....	199
lapatinib ditosylate .....	176	LONSURF ORAL TABLET 15-6.14 MG,	
LAZCLUZE ORAL TABLET 240 MG, 80		20-8.19 MG.....	349
MG .....	178	LOQTORZI.....	337



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

LORBRENA ORAL TABLET 100 MG, 25 MG.....	194	MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM.....	157, 166
LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....	308	MEDPURA ALCOHOL PADS 70 % EXTERNAL .....	157, 166
LUNSUMIO .....	208	MEIJER ALCOHOL SWABS PAD 70 % .....	157, 166
LUPRON DEPOT (1-MONTH).....	186, 187	MEIJER PEN NEEDLES 29G X 12MM .....	157, 166
LUPRON DEPOT (3-MONTH).....	186, 187	MEIJER PEN NEEDLES 31G X 6 MM	157, 166
LUPRON DEPOT (4-MONTH).....	186, 187	MEIJER PEN NEEDLES 31G X 8 MM	157, 166
LUPRON DEPOT (6-MONTH).....	186, 187	MEKINIST ORAL SOLUTION RECONSTITUTED.....	340
LUPRON DEPOT-PED (3-MONTH)....	188	MEKINIST ORAL TABLET 0.5 MG, 2 MG .....	341
LUPRON DEPOT-PED (6-MONTH)....	188	MEKTOVI.....	47
LYBALVI.....	227	MICRODOT PEN NEEDLE 31G X 6 MM .....	157, 166
LYNPARZA ORAL TABLET .....	228	MICRODOT PEN NEEDLE 32G X 4 MM .....	157, 166
LYTGOBI (12 MG DAILY DOSE).....	124	MICRODOT PEN NEEDLE 33G X 4 MM .....	157, 166
LYTGOBI (16 MG DAILY DOSE).....	124	mifepristone oral tablet 300 mg .....	205
LYTGOBI (20 MG DAILY DOSE).....	124	MIPLYFFA.....	25
<b>M</b>		MIRASORB SPONGES 2.....	157, 166
MAGELLAN INSULIN SAFETY SYR 29G X 1/2.....	157, 166	MM PEN NEEDLES 32G X 4 MM	157, 166
MAGELLAN INSULIN SAFETY SYR 30G X 5/16.....	157, 166	modafinil oral tablet 100 mg, 200 mg.....	209
MARGENZA.....	198	MONOJECT INSULIN SYRINGE 25G X 5/8 .....	158, 166
MAVENCLAD (10 TABS).....	64	MONOJECT INSULIN SYRINGE 27G X 1/2 .....	158, 166
MAVENCLAD (4 TABS).....	64	MONOJECT INSULIN SYRINGE 28G X 1/2 .....	158, 166
MAVENCLAD (5 TABS).....	64	MONOJECT INSULIN SYRINGE 29G X 1/2 .....	158, 166
MAVENCLAD (6 TABS).....	64	MONOJECT INSULIN SYRINGE 30G X 5/16 .....	158, 166
MAVENCLAD (7 TABS).....	64	MONOJECT INSULIN SYRINGE 31G X 5/16 .....	158, 166
MAVENCLAD (8 TABS).....	64	MONOJECT INSULIN SYRINGE U-100 1 ML.....	158, 166
MAVENCLAD (9 TABS).....	64	MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2 .....	158, 166
MAXICOMFORT II PEN NEEDLE 31G X 6 MM .....	157, 166	MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2 .....	158, 166
MAXI-COMFORT INSULIN SYRINGE 28G X 1/2.....	157, 166		
MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM.....	157, 166		
MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM.....	157, 166		
MAXICOMFORT SYR 27G X 1/2	157, 166		
MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG.....	297		
MAYZENT STARTER PACK.....	297		
MEDIC INSULIN SYRINGE 30G X 5/16 .....	157, 166		
MEDICINE SHOPPE PEN NEEDLES 29G X 12MM.....	157, 166		

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

MONOJECT ULTRA COMFORT	OJEMDA ORAL SUSPENSION
SYRINGE 30G X 5/16 ..... 158, 166	RECONSTITUTED ..... 338
morphine sulfate (concentrate) oral solution	OJEMDA ORAL TABLET ..... 338
100 mg/5ml ..... 137	OJJAARA ..... 207
MOUNJARO SUBCUTANEOUS	ONTRUZANT ..... 343
SOLUTION AUTO-INJECTOR ..... 133	ONUREG ..... 33
MVASI..... 44	OPDIVO ..... 220
<b>N</b>	OPDIVO QVANTIG ..... 221
NATPARA..... 238	OPDUALAG..... 222
NERLYNX ..... 211	OPSUMIT ..... 197
NEULASTA ONPRO..... 242	ORENCIA CLICKJECT..... 4, 5
NINLARO..... 174	ORENCIA INTRAVENOUS ..... 2, 3
nitisinone..... 219	ORENCIA SUBCUTANEOUS SOLUTION
NIVESTYM..... 118	PREFILLED SYRINGE ..... 4, 5
NORDITROPIN FLEXPRO	ORFADIN ORAL SUSPENSION..... 219
SUBCUTANEOUS SOLUTION PEN-	ORGOVYX..... 261
INJECTOR..... 302, 303	ORLISSA ORAL TABLET 150 MG, 200
NOVOFINE AUTOCOVER 30G X 8 MM	MG ..... 94
..... 158, 166	ORKAMBI ORAL TABLET ..... 196
NOVOFINE PEN NEEDLE 32G X 6 MM	ORSERDU ORAL TABLET 345 MG, 86
..... 158, 166	MG ..... 93
NOVOFINE PLUS PEN NEEDLE 32G X 4	OTEZLA ..... 23, 24
MM ..... 158, 166	oxandrolone oral ..... 235
NOVOTWIST PEN NEEDLE 32G X 5 MM	OZEMPIC (0.25 OR 0.5 MG/DOSE)..... 132
..... 158, 166	OZEMPIC (1 MG/DOSE) ..... 132
NUBEQA ..... 74	OZEMPIC (2 MG/DOSE) ..... 132
NUCALA SUBCUTANEOUS SOLUTION	<b>P</b>
AUTO-INJECTOR ..... 202, 203	pazopanib hcl ..... 240
NUCALA SUBCUTANEOUS SOLUTION	PC UNIFINE PENTIPS 31G X 5 MM.. 158,
PREFILLED SYRINGE 100 MG/ML, 40	166
MG/0.4ML ..... 202, 203	PC UNIFINE PENTIPS 31G X 6 MM.. 158,
NUCALA SUBCUTANEOUS SOLUTION	166
RECONSTITUTED ..... 202, 203	PC UNIFINE PENTIPS 31G X 8 MM.. 158,
NUPLAZID ORAL CAPSULE..... 250	166
NUPLAZID ORAL TABLET 10 MG... 250	PEGASYS SUBCUTANEOUS SOLUTION
NURTEC..... 273, 274	180 MCG/ML ..... 243
NYVEPRIA ..... 241	PEGASYS SUBCUTANEOUS SOLUTION
<b>O</b>	PREFILLED SYRINGE ..... 243
OCREVUS ..... 224	PEMAZYRE..... 246
OCREVUS ZUNOVO ..... 225	PEN NEEDLES 29G X 12MM ..... 158, 166
ODOMZO ..... 305	PEN NEEDLES 30G X 5 MM (OTC)... 158,
OFEV ..... 214, 215	166
OGIVRI..... 342	PEN NEEDLES 30G X 8 MM ..... 158, 166
OGSIVEO ORAL TABLET 100 MG, 150	PEN NEEDLES 31G X 5 MM (OTC)... 158,
MG, 50 MG..... 218	166

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

PEN NEEDLES 31G X 8 MM (OTC)... 158, 166	PRECISION SURE-DOSE SYRINGE 30G X 5/16..... 158, 166
PEN NEEDLES 32G X 4 MM (OTC)... 158, 166	PREFERRED PLUS INSULIN SYRINGE 28G X 1/2..... 158, 166
PEN NEEDLES 32G X 5 MM ..... 158, 166	PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM..... 159, 166
penicillamine oral tablet..... 247, 248	PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM..... 159, 166
PENTIPS 29G X 12MM (RX)..... 158, 166	PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM..... 159, 166
PENTIPS 31G X 5 MM (RX)..... 158, 166	PREVENT SAFETY PEN NEEDLES 31G X 6 MM..... 159, 166
PENTIPS 31G X 8 MM (RX)..... 158, 166	PREVENT SAFETY PEN NEEDLES 31G X 8 MM..... 159, 166
PENTIPS 32G X 4 MM (RX)..... 158, 166	PREVYMIS ORAL TABLET ..... 182
PENTIPS GENERIC PEN NEEDLES 29G X 12MM..... 158, 166	PRO COMFORT ALCOHOL PAD 70 % ..... 159, 166
PENTIPS GENERIC PEN NEEDLES 31G X 6 MM..... 158, 166	PRO COMFORT INSULIN SYRINGE 30G X 1/2..... 159, 166
PENTIPS GENERIC PEN NEEDLES 32G X 6 MM..... 158, 166	PRO COMFORT INSULIN SYRINGE 30G X 5/16..... 159, 166
PIP PEN NEEDLES 31G X 5MM 31G X 5 MM ..... 158, 166	PRO COMFORT INSULIN SYRINGE 31G X 5/16..... 159, 166
PIP PEN NEEDLES 32G X 4MM 32G X 4 MM ..... 158, 166	PRO COMFORT PEN NEEDLES 31G X 8 MM ..... 159, 166
PIQRAY (200 MG DAILY DOSE)..... 16	PRO COMFORT PEN NEEDLES 32G X 4 MM ..... 159, 166
PIQRAY (250 MG DAILY DOSE)..... 16	PRO COMFORT PEN NEEDLES 32G X 5 MM ..... 159, 166
PIQRAY (300 MG DAILY DOSE)..... 16	PRO COMFORT PEN NEEDLES 32G X 6 MM ..... 159, 166
pirfenidone oral capsule..... 251	PRODIGY INSULIN SYRINGE 28G X 1/2 ..... 159, 166
pirfenidone oral tablet 267 mg, 534 mg, 801 mg ..... 251	PRODIGY INSULIN SYRINGE 31G X 5/16 ..... 159, 166
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR..... 169	PROMACTA ORAL PACKET 12.5 MG, 25 MG ..... 97
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE ..... 169	PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG ..... 97
PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR ..... 169	PURE COMFORT ALCOHOL PREP PAD ..... 159, 166
PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 169	PURE COMFORT PEN NEEDLE 32G X 4 MM ..... 159, 166
POMALYST ..... 253	PURE COMFORT PEN NEEDLE 32G X 5 MM ..... 159, 166
posaconazole oral tablet delayed release 255	
PRECISION SUREDOSE PLUS SYR 29G X 1/2..... 158, 166	
PRECISION SURE-DOSE SYRINGE 28G X 1/2..... 158, 166	
PRECISION SURE-DOSE SYRINGE 29G X 1/2..... 158, 166	
PRECISION SURE-DOSE SYRINGE 30G X 3/8..... 158, 166	

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

PURE COMFORT PEN NEEDLE 32G X 6 MM .....	159, 166	REALITY INSULIN SYRINGE 28G X 1/2 .....	159, 166
PURE COMFORT PEN NEEDLE 32G X 8 MM .....	159, 166	REALITY INSULIN SYRINGE 29G X 1/2 .....	159, 166
PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM.....	159, 166	REALITY SWABS PAD.....	160, 166
PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM.....	159, 166	RELION ALCOHOL SWABS PAD .....	160, 166
PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM.....	159, 166	RELI-ON INSULIN SYRINGE 29G 0.3 ML.....	160, 166
PX SHORTLENGTH PEN NEEDLES 31G X 8 MM.....	159, 166	RELI-ON INSULIN SYRINGE 29G 0.5 ML.....	160, 166
pyrimethamine oral .....	257	RELI-ON INSULIN SYRINGE 29G X 1/2 .....	160, 166
<b>Q</b>		RELION INSULIN SYRINGE 31G X 15/64 .....	160, 166
QC ALCOHOL.....	159, 166	RELION MINI PEN NEEDLES 31G X 6 MM .....	160, 166
QC ALCOHOL SWABS PAD 70 % .....	159, 166	RELION PEN NEEDLES 31G X 6 MM.....	160, 166
QC BORDER ISLAND GAUZE PAD 2 .....	159, 166	RELION PEN NEEDLES 31G X 8 MM.....	160, 166
QINLOCK.....	277	RESTORE CONTACT LAYER PAD 2 .....	160, 166
QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM.....	159, 166	RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML .....	104, 105
QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM.....	159, 166	RETEVMO ORAL CAPSULE 40 MG, 80 MG .....	294
quinine sulfate oral.....	258	RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG .....	294
QULIPTA .....	29	REVUFORJ ORAL TABLET 110 MG, 160 MG .....	266
<b>R</b>		REZLIDHIA .....	229
RA ALCOHOL SWABS PAD 70 % .....	159, 166	REZUROCK.....	37
RA INSULIN SYRINGE 29G X 1/2.....	159, 166	RIABNI.....	282
RA INSULIN SYRINGE 30G X 5/16... ..	159, 166	RINVOQ.....	353, 354
ra isopropyl alcohol wipes .....	159, 166	RINVOQ LQ.....	353, 354
RA PEN NEEDLES 31G X 5 MM. ....	159, 166	RITUXAN HYCELA .....	280
RA PEN NEEDLES 31G X 8 MM. ....	159, 166	ROZLYTREK ORAL CAPSULE 100 MG, 200 MG .....	100
RA STERILE PAD 2 .....	159, 166	ROZLYTREK ORAL PACKET .....	101
RAYA SURE PEN NEEDLE 29G X 12MM .....	159, 166	RUBRACA .....	285
RAYA SURE PEN NEEDLE 31G X 4 MM .....	159, 166	RUXIENCE .....	283
RAYA SURE PEN NEEDLE 31G X 5 MM .....	159, 166	RYBELSUS .....	132
RAYA SURE PEN NEEDLE 31G X 6 MM .....	159, 166		

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

RYBREVANT .....	18	sorafenib tosylate .....	306
RYDAPT.....	204	SPRAVATO (56 MG DOSE).....	108
RYTELO.....	143	SPRAVATO (84 MG DOSE).....	108
<b>S</b>		STELARA INTRAVENOUS .....	357
SAFETY INSULIN SYRINGES 29G X 1/2		STELARA SUBCUTANEOUS	
.....	160, 166	SOLUTION 45 MG/0.5ML .....	355, 356
SAFETY INSULIN SYRINGES 30G X 1/2		STELARA SUBCUTANEOUS	
.....	160, 166	SOLUTION PREFILLED SYRINGE	355,
SAFETY INSULIN SYRINGES 30G X		356	
5/16 .....	160, 166	STERILE GAUZE PAD 2 .....	160, 166
SAFETY PEN NEEDLES 30G X 5 MM		STERILE PAD 2.....	160, 166
.....	160, 166	STIVARGA .....	260
SAFETY PEN NEEDLES 30G X 8 MM		STRENSIQ .....	27, 28
.....	160, 166	sunitinib malate.....	310
sapropterin dihydrochloride oral tablet...	287	SURE COMFORT ALCOHOL PREP PAD	
SB ALCOHOL PREP PAD 70 %...	160, 166	70 % .....	160, 166
SB INSULIN SYRINGE 29G X 1/2 .....	160,	SURE COMFORT INSULIN SYRINGE	
166		28G X 1/2.....	160, 166
SB INSULIN SYRINGE 30G X 5/16 ...	160,	SURE COMFORT INSULIN SYRINGE	
166		29G X 1/2.....	160, 166
SB INSULIN SYRINGE 31G X 5/16 ...	160,	SURE COMFORT INSULIN SYRINGE	
166		30G X 1/2.....	160, 166
SCEMBLIX ORAL TABLET 100 MG, 20		SURE COMFORT INSULIN SYRINGE	
MG, 40 MG.....	26	30G X 5/16.....	160, 166
SECURESAFE INSULIN SYRINGE 29G		SURE COMFORT INSULIN SYRINGE	
X 1/2.....	160, 166	31G X 1/4.....	160, 166
SECURESAFE SAFETY PEN NEEDLES		SURE COMFORT INSULIN SYRINGE	
30G X 8 MM.....	160, 166	31G X 5/16.....	160, 166
SEROSTIM SUBCUTANEOUS		SURE COMFORT PEN NEEDLES 29G X	
SOLUTION RECONSTITUTED 4 MG,		12.7MM .....	161, 166
5 MG, 6 MG.....	304	SURE COMFORT PEN NEEDLES 30G X	
SIGNIFOR .....	239	8 MM .....	161, 166
sildenafil citrate oral tablet 20 mg .....	296	SURE COMFORT PEN NEEDLES 31G X	
SIRTURO .....	35	5 MM .....	161, 166
SKYRIZI.....	278, 279	SURE COMFORT PEN NEEDLES 31G X	
SKYRIZI (150 MG DOSE) .....	278, 279	6 MM .....	161, 166
SKYRIZI PEN .....	278, 279	SURE COMFORT PEN NEEDLES 31G X	
SM ALCOHOL PREP PAD .....	160, 166	8 MM .....	161, 166
SM ALCOHOL PREP PAD 6-70 %		SURE COMFORT PEN NEEDLES 32G X	
EXTERNAL .....	160, 166	4 MM (OTC).....	161, 166
SM GAUZE PAD 2 .....	160, 166	SURE COMFORT PEN NEEDLES 32G X	
sodium oxybate .....	299	4 MM (RX).....	161, 166
SOMATULINE DEPOT		SURE COMFORT PEN NEEDLES 32G X	
SUBCUTANEOUS SOLUTION 60		6 MM .....	161, 166
MG/0.2ML, 90 MG/0.3ML .....	175	SURE-JECT INSULIN SYRINGE 31G X	
SOMAVERT.....	244	5/16 .....	161, 166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

SURE-PREP ALCOHOL PREP PAD 70 % ..... 161, 166	TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM ..... 161, 166
SURGICAL GAUZE SPONGE PAD 2 161, 166	TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM..... 161, 166
SYMPAZAN..... 65	TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM..... 161, 166
SYNRIBO ..... 230	TOPCARE ULTRA COMFORT INS SYR 29G X 1/2..... 161, 166
<b>T</b>	TOPCARE ULTRA COMFORT INS SYR 30G X 5/16..... 161, 166
TABRECTA ..... 57	TOPCARE ULTRA COMFORT INS SYR 31G X 5/16..... 161, 166
tadalafil oral tablet 2.5 mg, 5 mg ..... 312	torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg ..... 111
TAFINLAR ORAL CAPSULE ..... 70	TRAMADOL HCL ORAL SOLUTION 339
TAFINLAR ORAL TABLET SOLUBLE 71	TRAZIMERA ..... 346
TAGRISSE ..... 234	TRELSTAR MIXJECT ..... 350
TALVEY..... 314	TREMFYA INTRAVENOUS ..... 135, 136
TALZENNA ..... 313	TREMFYA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 135, 136
TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG..... 212	TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 135, 136
TAVNEOS ..... 30	tretinoin external cream ..... 336
TAZVERIK..... 316	trientine hcl oral capsule 250 mg ..... 348
TECVAYLI..... 318	TRUE COMFORT ALCOHOL PREP PADS PAD 70 % ..... 161, 166
TEGLUTIK..... 272	TRUE COMFORT INSULIN SYRINGE 30G X 1/2..... 161, 166
TEPMETKO ..... 320	TRUE COMFORT INSULIN SYRINGE 30G X 5/16..... 161, 166
TERIPARATIDE SUBCUTANEOUS SOLUTION PEN-INJECTOR 620 MCG/2.48ML ..... 321	TRUE COMFORT INSULIN SYRINGE 31G X 5/16..... 161, 166
TERUMO INSULIN SYRINGE 29G X 1/2 ..... 161, 166	TRUE COMFORT INSULIN SYRINGE 32G X 5/16..... 161, 166
testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml) ..... 323	TRUE COMFORT PEN NEEDLES 31G X 5 MM ..... 161, 166
testosterone enanthate intramuscular solution..... 324	TRUE COMFORT PEN NEEDLES 31G X 6 MM ..... 161, 166
testosterone gel 1.62 % transdermal ..... 322	TRUE COMFORT PEN NEEDLES 32G X 4 MM ..... 161, 166
testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)..... 322	TRUE COMFORT PRO ALCOHOL PREP PAD 70 % ..... 161, 166
tetrabenazine ..... 325	TRUE COMFORT PRO INSULIN SYR 30G X 1/2..... 161, 166
TEVIMBRA..... 327	
THALOMID ..... 326	
THERAGAUZE PAD 2..... 161, 166	
TIBSOVO ..... 173	
TIGLUTIK SUSPENSION 50 MG/10ML ORAL..... 272	
TIVDAK ..... 328	
TODAYS HEALTH PEN NEEDLES 29G X 12MM..... 161, 166	

## Valor Health Plan 2025 Formulary Prior Authorization Criteria

TRUE COMFORT PRO INSULIN SYR 30G X 5/16.....	161, 166	TRUEPLUS PEN NEEDLES 31G X 6 MM .....	162, 166
TRUE COMFORT PRO INSULIN SYR 31G X 5/16.....	161, 162, 166	TRUEPLUS PEN NEEDLES 31G X 8 MM .....	162, 166
TRUE COMFORT PRO INSULIN SYR 32G X 5/16.....	162, 166	TRUEPLUS PEN NEEDLES 32G X 4 MM .....	162, 166
TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM.....	162, 166	TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR .....	131
TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM.....	162, 166	TRUQAP ORAL TABLET .....	56
TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM.....	162, 166	TRUQAP TABLET THERAPY PACK 160 MG ORAL .....	56
TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM.....	162, 166	TRUSELTIQ (100MG DAILY DOSE)..	145
TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM.....	162, 166	TRUSELTIQ (125MG DAILY DOSE)..	145
TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM.....	162, 166	TRUSELTIQ (50MG DAILY DOSE)....	145
TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM.....	162, 166	TRUSELTIQ (75MG DAILY DOSE)....	145
TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM.....	162, 166	TRUXIMA .....	281
TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM.....	162, 166	TUKYSA ORAL TABLET 150 MG, 50 MG .....	351
TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM.....	162, 166	TURALIO .....	249
TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM.....	162, 166	TYMLOS .....	1
TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM.....	162, 166	<b>U</b>	
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM.....	162, 166	UBRELVY.....	352
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM.....	162, 166	ULTICARE INSULIN SAFETY SYR 29G X 1/2.....	162, 166
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM.....	162, 166	ULTICARE INSULIN SYRINGE 28G X 1/2 .....	162, 166
TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM.....	162, 166	ULTICARE INSULIN SYRINGE 29G X 1/2 .....	162, 166
TRUEPLUS INSULIN SYRINGE 28G X 1/2 .....	162, 166	ULTICARE INSULIN SYRINGE 30G X 1/2 .....	162, 166
TRUEPLUS INSULIN SYRINGE 29G X 1/2 .....	162, 166	ULTICARE INSULIN SYRINGE 30G X 5/16 .....	162, 163, 166
TRUEPLUS INSULIN SYRINGE 30G X 5/16 .....	162, 166	ULTICARE INSULIN SYRINGE 31G X 1/4 .....	163, 166
TRUEPLUS INSULIN SYRINGE 31G X 5/16 .....	162, 166	ULTICARE INSULIN SYRINGE 31G X 5/16 .....	163, 166
TRUEPLUS PEN NEEDLES 29G X 12MM .....	162, 166	ULTICARE MICRO PEN NEEDLES 32G X 4 MM.....	163, 166
TRUEPLUS PEN NEEDLES 31G X 5 MM .....	162, 166	ULTICARE MINI PEN NEEDLES 30G X 5 MM .....	163, 166
		ULTICARE MINI PEN NEEDLES 31G X 6 MM .....	163, 166
		ULTICARE MINI PEN NEEDLES 32G X 6 MM .....	163, 166
		ULTICARE PEN NEEDLES 29G X 12.7MM (OTC).....	163, 166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

ULTICARE PEN NEEDLES 29G X 12.7MM (RX).....	163, 166	ULTILET PEN NEEDLE 31G X 5 MM	164, 166
ULTICARE PEN NEEDLES 31G X 5 MM.....	163, 166	ULTILET PEN NEEDLE 31G X 8 MM	164, 166
ULTICARE SHORT PEN NEEDLES 30G X 8 MM.....	163, 166	ULTILET PEN NEEDLE 32G X 4 MM	164, 166
ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC).....	163, 166	ULTRA COMFORT INSULIN SYRINGE 30G X 5/16.....	164, 166
ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX).....	163, 166	ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM.....	163, 166	ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM.....	163, 166	ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM.....	163, 166	ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM.....	163, 166	ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM.....	163, 166	ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16.....	164, 166
ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM.....	163, 166	ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16.....	164, 166
ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2.....	163, 166	ULTRA FLO INSULIN SYRINGE 29G X 1/2.....	164, 166
ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16.....	163, 166	ULTRA FLO INSULIN SYRINGE 30G X 1/2.....	164, 166
ULTILET ALCOHOL SWABS PAD ...	163, 166	ULTRA FLO INSULIN SYRINGE 30G X 5/16.....	164, 166
ULTILET INSULIN SYRINGE 30G X 1/2.....	163, 166	ULTRA FLO INSULIN SYRINGE 31G X 5/16.....	164, 166
ULTILET INSULIN SYRINGE 30G X 5/16.....	163, 166	ULTRA THIN PEN NEEDLES 32G X 4 MM.....	164, 166
ULTILET INSULIN SYRINGE 31G X 1/4.....	163, 166	ULTRACARE INSULIN SYRINGE 30G X 1/2.....	164, 165, 166
ULTILET INSULIN SYRINGE 31G X 15/64.....	163, 166	ULTRACARE INSULIN SYRINGE 30G X 5/16.....	165, 166
ULTILET INSULIN SYRINGE 31G X 5/16.....	163, 164, 166	ULTRACARE INSULIN SYRINGE 31G X 5/16.....	165, 166
ULTILET INSULIN SYRINGE SHORT 30G X 1/2.....	164, 166	ULTRACARE PEN NEEDLES 31G X 5 MM.....	165, 166
ULTILET INSULIN SYRINGE SHORT 30G X 5/16.....	164, 166	ULTRACARE PEN NEEDLES 31G X 6 MM.....	165, 166
ULTILET INSULIN SYRINGE SHORT 31G X 5/16.....	164, 166	ULTRACARE PEN NEEDLES 31G X 8 MM.....	165, 166
ULTILET PEN NEEDLE 29G X 12.7MM.....	164, 166	ULTRACARE PEN NEEDLES 32G X 4 MM.....	165, 166



## Valor Health Plan 2025 Formulary Prior Authorization Criteria

ULTRACARE PEN NEEDLES 32G X 5 MM .....	165, 166	UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	165, 166
ULTRACARE PEN NEEDLES 32G X 6 MM .....	165, 166	UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	165, 166
ULTRACARE PEN NEEDLES 33G X 4 MM .....	165, 166	UNIFINE ULTRA PEN NEEDLE 31G X 5 MM .....	165, 166
ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2.....	164, 166	UNIFINE ULTRA PEN NEEDLE 31G X 6 MM .....	165, 166
ULTRA-THIN II INS SYR SHORT 30G X 5/16 .....	164, 166	UNIFINE ULTRA PEN NEEDLE 31G X 8 MM .....	165, 166
ULTRA-THIN II INS SYR SHORT 31G X 5/16 .....	164, 166	UNIFINE ULTRA PEN NEEDLE 32G X 4 MM .....	165, 166
ULTRA-THIN II INSULIN SYRINGE 29G X 1/2.....	164, 166	UPTRAVI INTRAVENOUS.....	292
ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM.....	164, 166	UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG .....	292
ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM.....	164, 166	UPTRAVI TITRATION.....	292
ULTRA-THIN II PEN NEEDLES 29G X 12.7MM .....	164, 166	<b>V</b>	
UNIFINE PEN NEEDLES 32G X 4 MM .....	165, 166	VALCHLOR.....	201
UNIFINE PENTIPS 29G X 12MM	165, 166	VALUE HEALTH INSULIN SYRINGE 29G X 1/2.....	165, 166
UNIFINE PENTIPS 31G X 6 MM.	165, 166	VANFLYTA .....	259
UNIFINE PENTIPS 31G X 8 MM.	165, 166	VANISHPOINT INSULIN SYRINGE 29G X 5/16.....	165, 166
UNIFINE PENTIPS PLUS 29G X 12MM .....	165, 166	VANISHPOINT INSULIN SYRINGE 30G X 3/16.....	165, 166
UNIFINE PENTIPS PLUS 31G X 6 MM .....	165, 166	VANISHPOINT INSULIN SYRINGE 30G X 5/16.....	165, 166
UNIFINE PENTIPS PLUS 32G X 4 MM .....	165, 166	VEGZELMA.....	43
UNIFINE PROTECT PEN NEEDLE 30G X 5 MM .....	165, 166	VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	362
UNIFINE PROTECT PEN NEEDLE 30G X 8 MM .....	165, 166	VENCLEXTA STARTING PACK .....	362
UNIFINE PROTECT PEN NEEDLE 32G X 4 MM .....	165, 166	VEOZAH .....	117
UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	165, 166	VERIFINE INSULIN PEN NEEDLE 29G X 12MM.....	165, 166
UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	165, 166	VERIFINE INSULIN PEN NEEDLE 31G X 5 MM.....	165, 166
UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	165, 166	VERIFINE INSULIN PEN NEEDLE 32G X 6 MM.....	165, 166
UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	165, 166	VERIFINE INSULIN SYRINGE 29G X 1/2 .....	165, 166
		VERIFINE INSULIN SYRINGE 31G X 5/16 .....	165, 166
		VERIFINE PLUS PEN NEEDLE 31G X 5 MM .....	166

## Valor Health Plan 2025 Formulary

### Prior Authorization Criteria

VERIFINE PLUS PEN NEEDLE 31G X 8 MM .....	166	XOLAIR .....	231, 233
VERIFINE PLUS PEN NEEDLE 32G X 4 MM .....	166	XOSPATA .....	128
VERQUVO .....	363	XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG .....	293
VERZENIO.....	6	XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG..	293
vigabatrin .....	364	XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	293
vigadrone.....	364	XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG..	293
vigpoder .....	364	XPOVIO (60 MG TWICE WEEKLY)...	293
VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	177	XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG..	293
VITRAKVI ORAL SOLUTION .....	177	XPOVIO (80 MG TWICE WEEKLY)...	293
VIZIMPRO .....	72	XTANDI ORAL CAPSULE.....	102
VONJO .....	236	XTANDI ORAL TABLET 40 MG, 80 MG .....	102
VORANIGO .....	366	XYOSTED .....	324
voriconazole oral suspension reconstituted .....	367	<b>Y</b>	
VOSEVI.....	301	YERVOY .....	171
VOWST .....	113	YONSA.....	8
VP INSULIN SYRINGE 29G X 1/2 .....	166	<b>Z</b>	
VUMERITY .....	84	ZEJULA ORAL CAPSULE .....	216
VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML.....	121	ZEJULA ORAL TABLET.....	216
VYLOY.....	371	ZELBORAF.....	361
<b>W</b>		ZEVRX STERILE ALCOHOL PREP PAD PAD 70 % .....	166
WEBCOL ALCOHOL PREP LARGE PAD 70 % .....	166	ZIIHERA.....	368
WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM.....	166	ZIRABEV .....	45
WELIREG.....	38	ZOLADEX.....	134
WINREVAIR.....	307	ZTALMY .....	126
<b>X</b>		ZTLIDO .....	191
XALKORI ORAL CAPSULE.....	68	ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....	372
XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG .....	69	ZYDELIG .....	140
XDEMVI .....	195	ZYKADIA ORAL TABLET .....	59
XELJANZ.....	334, 335	ZYNLONTA.....	193
XELJANZ XR .....	334, 335	ZYNYZ.....	265
XERMELO .....	319		
XGEVA.....	80		
XIFAXAN ORAL TABLET 200 MG, 550 MG .....	269		